Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis

Authors and Affiliations: Carolyn M. Walsh[1‡], Rose Z. Hill[1‡], Jamie Schwendinger-Schreck[1], Jacques Deguine[1], Emily C. Brock[1], Natalie Kucirek[1], Ziad Rifi[1], Jessica Wei[2], Karsten Gronert[2], Rachel B. Brem[3,4], Gregory M. Barton[1], Diana M. Bautista[1,5]

1. Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.
2. Vision Science Program, School of Optometry, University of California, Berkeley, CA 94720, USA.
3. Department of Plant and Microbial Biology, University of California, Berkeley, CA 94720, USA.
4. Buck Institute for Research on Aging, Novato, CA 94945, USA.
5. Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720, USA.

‡ These authors contributed equally and order determined by coin toss.

Abstract

Chronic itch remains a highly prevalent disorder with limited treatment options. Most chronic itch diseases are thought to be driven by both the nervous and immune systems, but the fundamental molecular and cellular interactions that trigger the development of itch and the acute-to-chronic itch transition remain unknown. Here, we show that skin-infiltrating neutrophils are key initiators of itch in atopic dermatitis, the most prevalent chronic itch disorder. Neutrophil depletion significantly attenuated itch-evoked scratching in a mouse model of atopic dermatitis. Neutrophils were also required for several key hallmarks of chronic itch, including skin hyperinnervation, enhanced expression of itch signaling molecules, and upregulation of inflammatory cytokines, activity-induced genes, and markers of neuropathic itch. Finally, we demonstrate that neutrophils are required for induction of CXCL10, a ligand of the CXCR3 receptor that promotes itch via activation of sensory neurons, and we find that that CXCR3 antagonism attenuates chronic itch.

Introduction

Chronic itch is a debilitating disorder that affects millions of people worldwide.[1–3] It is a symptom of a number of skin diseases and systemic disorders, as well as a side effect of a growing list of medications. Like chronic pain, chronic itch can be a disease in and of itself.[4–6] Unlike acute itch, which can facilitate removal of crawling insects, parasites, or irritants, persistent scratching in chronic itch disorders has no discernable benefit; scratching damages skin, leading to secondary infection, disfiguring lesions, and exacerbation of disease severity.[2,7,8] The most common chronic itch disorder is atopic dermatitis (AD; commonly known as eczema), which affects fifteen million people in the United States alone.[9] Severe AD can trigger the atopic march, where chronic itch and inflammation progress to food allergy, allergic rhinitis, and asthma.[9,10]

Little is known about the underlying mechanisms that drive chronic itch pathogenesis. As such, studies of human chronic itch disorders have sought to identify candidate mechanisms of disease progression. A number of studies have identified biomarkers and disease genes in itchy human AD lesions.[11–15] Indeed, a recent study compared the transcriptomes of healthy skin to itchy and non-itchy skin from psoriasis and AD patients, revealing dramatic changes in expression of genes associated with cytokines, immune cells, epithelial cells, and sensory neurons.[16] However, due to the difficulty in staging lesion development and obtaining staged samples from patients, there is currently no temporal map of when individual molecules and cell types contribute to chronic itch pathogenesis. Furthermore, the use of human patient data does not allow for rigorous mechanistic study of how disease genes contribute to chronic itch. To this end, we used a well-characterized inducible animal model of itch to define where, when, and how these genes identified from patient data contribute to chronic itch pathogenesis.

We employed the MC903 mouse model of AD and the atopic march[17–21] to provide a framework within which to identify the molecules and cells that initiate the development of atopic itch. The MC903 model is ideal for our approach because of its highly reproducible phenotypes that closely resemble human AD and the ability to induce the development of lesions and scratching.[18–20,22–24] By contrast, it is difficult to synchronously time the development of lesions in commonly used genetic models of AD, such as filaggrin mutant mice or Nc/Nga mice. Another advantage of the MC903 model is that it displays collectively more hallmarks of human AD than any one particular genetic mouse model. For example, the commonly used IL-31^{tg} overexpressor model[25,26] lacks strong Th2 induction,[27] and itch behaviors have not yet been rigorously characterized in the keratinocyte-TSLP overexpressor model. As MC903 is widely used to study the chronic phase of AD, we hypothesized that MC903 could also be used to

define the early mechanisms underlying the development of chronic itch, beginning with healthy skin. We performed RNA-seq of skin at key time points in the model. We complemented this approach with measurements of itch behavior and immune cell infiltration. The primary goal of our study was to identify the inciting molecules and cell types driving development of chronic itch. To that end, we show that infiltration of neutrophils into skin is required for development of chronic itch. Additionally, we demonstrate that neutrophils direct early hyperinnervation of skin, and the upregulation of itch signaling molecules and activity-induced genes in sensory neurons. Finally, we identify CXCL10/CXCR3 signaling as a key link between infiltrating neutrophils and sensory neurons that drives itch behaviors.

MC903 triggers rapid changes in expression of skin barrier, epithelial cell-derived cytokine, and axon guidance genes

Although a variety of AD- and chronic itch-associated genes have been identified, when and how they contribute to disease pathogenesis is unclear. Using RNA-seq of MC903-treated skin, we observed distinct temporal patterns by which these classes of genes are differentially expressed across the first eight days of the model (Figure 1A-B, Figure 1-Figure Supplement 1A). Overall, we found that 62% of genes from a recent study of human chronic itch lesions[16] (Figure 1-Figure Supplement 1A) and 67% of AD-related genes (Figure 1B) were significantly changed for at least one of the time points examined, suggesting that the MC903 mouse model recapitulates many key transcriptional changes occuring in human chronic itch and AD. MC903 dramatically alters the transcriptional profile of keratinocytes by derepressing genomic loci under the control of the Vitamin D Receptor. In line with rapid changes in transcription, proteases (*Klk6*, *Klk13*, among others) and skin barrier genes (*Cdhr1*) changed as early as six hours after the first treatment, before mice begin scratching (Figure 1B). Increased protease activity in AD skin is thought to promote breakdown of the epidermal barrier and release of inflammatory cytokines from keratinocytes.[28,29] One such cytokine, thymic stromal lymphopoetin (TSLP) is a key inducer of the Type 2 immune response, which is characteristic of human AD and the MC903 model, via signaling in $CD4^+$ T cells, basophils, and other immune cells.[19,20,30–33] Beginning at day two, before any significant itch-evoked scratching (Figure 1C), immune cell infiltration (Figure 1E-G, Figure 1-Figure Supplements 3A, 4A, 5A-C), or skin lesions (data not shown)[23] were observed, we saw increases in *Tslp*, as well as several other epithelial-derived cytokines, including the neutrophil chemoattractant genes *Cxcl1, Cxcl2, Cxcl3,* and *Cxcl5* (Figure 1D). To ask whether upregulation of these chemokine genes was dependent on protease activity, we treated human keratinocytes with the Protease Activated Receptor 2 agonist SLIGRL. SLIGRL treatment triggered increased expression of several of these chemokine genes, including *IL8*, the human ortholog of mouse *Cxcl1/Cxcl2,* and *CXCL2* (Figure 1-Figure Supplement 6A). These increases occurred after a few hours of exposure to SLIGRL, suggesting that increased protease activity can rapidly trigger increases in neutrophil chemoattractants in skin, similar to what we observe in MC903-treated mouse skin.

Unexpectedly, in the skin we observed early changes in a number of transcripts encoding neuronal outgrowth factors (*Ngf*, *Artn*) and axon pathfinding molecules (*Slit1*, *Sema3d, Sema3a*), some of which are directly implicated in chronic itch[34–38]; Figure 1-Figure Supplement 7A), prior to when mice began scratching. We thus used immunohistochemistry (IHC) of whole-mount skin to examine innervation at this time point. We saw increased innervation of lesions at day two but not day one of the model (Figure 1H-I, Figure 1-Figure Supplement 8A). Our RNA-seq data showed elevation in skin CGRP transcript, along with other markers of peptidergic nerve endings, specifically at day 2. Indeed, we saw an increase in $CGRP^+$ innervation of skin at day 2 (Figure 1J, Figure 1-Figure Supplement 9A), which suggests that elevation of neuronal transcripts in skin is due to hyperinnervation of peptidergic itch and/or pain fibers. The increased innervation was surprising because such changes had previously only been reported in mature

lesions from human chronic itch patients.[16,39–44] Our findings suggest that early hyperinnervation is promoted by local signaling in the skin and is independent of the itch-scratch cycle.

Neutrophils are the first immune cells to infiltrate AD skin

By day five, mice exhibited robust itch behaviors (Figure 1C) and stark changes in a number of AD disease genes (Figure 1A-B). For example, loss-of-function mutations in filaggrin (*FLG)* are a major risk factor for human eczema.[45,46] Interestingly, *Flg2* levels sharply decreased at day five. In parallel, we saw continued and significant elevation in neutrophil and basophil chemoattractant genes (*Cxcl1,2,3,5*, and *Tslp*, Figure 1D). Using flow cytometry, we observed a number of infiltrating immune cells in the skin at day 5. Of these, we neutrophils were the most abundant immune cell subtype (Figure 1E, Figure 1-Figure Supplement 3A). It was not until day eight that we observed the classical AD-associated immune signature in the skin,[47] with upregulation of *Il4, Il33* and other Th2-associated genes (Figure 1B, Figure 1D). We also observed increases in the T cell chemoattractant genes *Cxcl9, Cxcl10,* and *Cxcl11* (Figure 1D), which are thought to be hallmarks of chronic AD lesions in humans.[48,49] Neutrophils and a number of other immune cells that started to infiltrate on day five were robustly elevated in skin by day eight, including basophils (Figure 1F), $CD4^+$ T cells (Figure 1G, Figure 1-Figure Supplement 4A), eosinophils (Figure 1-Figure Supplement 5C), and mast cells (Figure 1-Figure Supplement 5B), but not inflammatory monocytes (Figure 1-Figure Supplement 5A).

$CD4^+$ T cells are ubiquitous in mature human AD lesions[50] and promote chronic AD itch and inflammation. More specifically, they play a key role in IL4Rα-dependent sensitization of pruriceptors in the second week of the MC903 model.[22] Thus, we were quite surprised to find that itch behaviors preceded significant $CD4^+$ T cell infiltration. Therefore, neutrophils drew our attention as potential early mediators of MC903 itch. While neutrophil infiltration is a hallmark of acute inflammation, it remains unclear whether neutrophils contribute to the pathogenesis of chronic itch. Moreover, neutrophils release known pruritogens, including proteases, reactive oxygen species, and/or histamine, inflammatory lipids, and cytokines that sensitize and/or activate pruriceptors.[51,52] Increased levels of the prostaglandin PGE_2 and the neutrophil-specific leukotriene LTB_4 have also been reported in skin of AD patients.[53] Indeed, by mass spectrometry, we observed increases in several of these inflammatory lipids, PGD_2 and PGE_2, as well as LTB_4 and its precursor 5-HETE (Figure 1-Figure Supplement 10A) in MC903-treated skin, implicating neutrophils in driving AD itch and inflammation. Thus, we next tested the requirement of neutrophils to itch in the MC903 model.

Neutrophils are required for early itch behaviors in the MC903 model of AD

We first asked whether neutrophils, the most abundant population of infiltrating immune cells in this chronic itch model, were required for MC903-evoked itch. Systemic depletion of neutrophils using daily injections of an anti-Gr1 (aGr1) antibody[54,55] dramatically attenuated itch-evoked scratching through the first eight days of the model (Figure 2A). Consistent with a key role for neutrophils in driving chronic itch, our depletion strategy significantly and selectively reduced circulating and skin infiltrating neutrophils on days five and eight, days on which control, but not depleted mice, scratched robustly (Figure 2B; Figure 2-Figure Supplement 1A-C). In contrast, basophils and $CD4^+$ T cells continued to infiltrate the skin following aGr1 treatment (Figure 2C-D), suggesting that these cells are not required for early MC903 itch.

We next used the cheek model of acute itch[56] to ask whether neutrophil recruitment is sufficient to trigger scratching behaviors. As expected, we observed significant and selective recruitment of neutrophils to cheek skin within 15 minutes after CXCL1 injection (Figure 2-Figure Supplement 2A-B). CXCL1 injection also triggered robust scratching behaviors (Figure 2E) on a similar time course to neutrophil infiltration (Figure 2-Figure Supplement 2B). Thus, we next

acutely depleted neutrophils with aGr1 to determine whether neutrophils were required for CXCL1-evoked acute itch. Indeed, aGr1-treatment rapidly reduced circulating neutrophils (Figure 2-Figure Supplement 2C) and resulted in a dramatic loss of CXCL1-evoked itch behaviors (Figure 2C). This effect was specific to neutrophil-induced itch, as injection of chloroquine, a pruritogen that directly activates pruriceptors to trigger itch, still triggered robust scratching in aGr1-treated animals (Figure 2-Figure Supplement 3A). Given that CXCL1 has been shown to directly excite and/or sensitize sensory neurons,[57,58] it is possible that the mechanism by which CXCL1 elicits itch may also involve neuronal pathways. However, our results show that CXCL1-mediated neutrophil infiltration is sufficient to drive acute itch behaviors, and that neutrophils are necessary for itch in the MC903 model.

We also examined MC903-evoked itch behaviors in mice deficient in *Crlf2*, the gene encoding the TSLP Receptor (TSLPR$^{-/-}$ mice[59]). TSLPR is expressed by both immune cells and sensory neurons and is a key mediator of AD in humans and in mouse models.[18–20,31,60] Surprisingly, MC903-treated TSLPR$^{-/-}$ mice displayed robust scratching behaviors through the first eight days of the model (Figure 2F). In contrast to our results in aGr1-injected mice, TSLPR$^{-/-}$ mice displayed robust neutrophil infiltration (Figure 2G), but completely lacked basophil and CD4^{+} T cell infiltration into the skin (Figure 2H-I, Figure 2-Figure Supplement 4A), and additionally displayed a reduction in mast cells (Figure 2-Figure Supplement 4A). These results suggest that basophils and CD4^{+} T cells are not required for early itch and further support an inciting role for neutrophils. Previous studies have shown that TSLP drives the expression of Type 2 cytokines and related immune cells that promote itch and inflammation in mature AD skin lesions.[18–20,31,60] Consistent with a later role for TSLP signaling in AD, we did observe a significant reduction in itch-evoked scratching in TSLPR$^{-/-}$ mice in the second week of the model (Figure 2F). Thus, our data support a model in which neutrophils are necessary for initiation of AD and itch behaviors early in the development of AD, whereas TSLPR signaling mediates the recruitment of basophils and CD4^{+} T cells to promote later stage itch and chronic inflammation.

The incomplete loss of itch behaviors on day 12 in the TSLPR$^{-/-}$ animals (Figure 2F) raised the question of whether neutrophils might also contribute to itch during the second week of the MC903 model. To directly answer this question, we measured neutrophil infiltration and itch-evoked scratching on day 12 in mice that received either aGr1 or PBS on days 8-11 of the model to selectively deplete neutrophils solely during the second week. Neutrophil depletion in the second week with aGr1 robustly decreased skin-infiltrating neutrophils (Figure 2J), and substantially reduced scratching behaviors at day 12 (Figure 2K), supporting a role for neutrophils in chronic itch. Interestingly, we observed a 79% mean reduction in time spent scratching after neutrophil depletion at day 12, whereas loss of TSLPR effected a 44% reduction in time spent scratching. We speculate that neutrophils and TSLP signaling comprise independent mechanisms that together account for the majority of AD itch. In order to ascertain whether neutrophils could be salient players in other models of AD, and not just MC903, we measured neutrophil infiltration into ear skin in the 1-fluoro-2,4-dinitrobenzene (DNFB) model of atopic dermatitis, which relies on hapten-induced sensitization to drive increased IgE, mixed Th1/Th2 cytokine response, skin thickening, inflammation, and robust scratching behaviors in mice.[61–63] Indeed, neutrophils also infiltrated DNFB- but not vehicle-treated skin (Figure 2-Figure Supplement 5A). Taken together, these observations are complementary to published datasets showing evidence for neutrophil chemokines and transcripts in human AD lesions.[11,12,13–15] Overall, our data support a key role for neutrophils in promoting AD itch and inflammation.

MC903 drives rapid and robust changes in the peripheral and central nervous systems

But how do neutrophils drive AD itch? Itchy stimuli are detected and transduced by specialized subsets of peripheral somatosensory neurons. Thus, to answer this question we first profiled the

transcriptional changes in somatosensory neurons in the MC903 model, which were previously unstudied. In general, little is known regarding neuronal changes in chronic itch. Our initial examination of early hyperinnervation and changes in axon guidance molecules in skin suggested that neurons are indeed affected early on in the MC903 model, before the onset of itch-evoked scratching behaviors. In contrast to the skin, where we saw many early transcriptional changes, we did not see any significant transcriptional changes in the trigeminal ganglia (TG) until five days after the first treatment, and in total only 84 genes were differentially expressed through the eighth day (Figure 3A-B). These hits included genes related to excitability of itch sensory neurons,[51,64] neuroinflammatory genes,[65] and activity-induced or immediate early genes (Figure 3A). Interestingly, we observed enrichment of neuronal markers expressed by one specific subset of somatosensory neurons that are dedicated to itch (*Il31ra, Osmr, Trpa1, Cysltr2,* and *Nppb*), termed "NP3" neurons.[51,64,66,67] Similar to what has been reported in mouse models of chronic pain, we observed changes in neuroinflammatory (*Bdnf, Nptx1, Nptx2, Nptxr*) and immune genes (*Itk, Cd19, Rag, Tmem173*). However, these transcriptional changes occurred just a few days after itch onset, in contrast to the slow changes in nerve injury and pain models that occur over weeks, indicating that neuropathic changes may occur sooner than previously thought in chronic itch. These changes occurred in tandem with the onset of scratching behaviors (Figure 1C), suggesting that the early molecular and cellular changes we observed by this time point may be important for development or maintenance of itch-evoked scratching.

The changes we observed in immune-related genes in the TG were suggestive of infiltration or expansion of immune cell populations, which has been reported in models of nerve injury and chronic pain, but has never been reported in chronic itch. To validate our observations, we used IHC to ask whether $CD45^+$ immune cells increase in the TG. We observed a significant increase in TG immune cell counts at day eight but not day five (Figure 3C-F, Figure 3-Figure Supplement 1A-D). Because we observed such dramatic expression changes in the TG on day eight of the model, we postulated that the CNS may also be affected by this time point. Thus, we performed RNA-seq on spinal cord segments that innervate the MC903-treated rostral back skin of mice. To date, only one study has examined changes in the spinal cord during chronic itch.[68] The authors showed that upregulation of the STAT3-dependent gene *Lcn2* occurred three weeks after induction of chronic itch and was essential for sustained scratching behaviors. Surprisingly, we saw upregulation of *Lcn2* on day eight of the MC903 model and, additionally, we observed robust induction of immediate early genes (*Fos, Junb,* Figure 3G), suggesting that MC903 itch drives activity-dependent changes in the spinal cord as early as one week after beginning treatment. Together, our findings show that sustained itch and inflammation can drive changes in the PNS and CNS much sooner than previously thought, within days rather than weeks after the onset of scratching. We next set out to explore how loss of neutrophils impacts the molecular changes observed in skin and sensory neurons in the MC903 model, and which of these changes might contribute to neutrophil-dependent itch.

Neutrophils are required for upregulation of select itch- and atopic-related genes, including the itch-inducing chemokine CXCL10

To ask how neutrophils promote itch in the MC903 model, we examined the transcriptional changes in skin and sensory ganglia isolated from non-itchy neutrophil-depleted animals and from the $TSLPR^{-/-}$ mice, which scratched robustly. A number of AD-associated cytokines that were upregulated in control MC903 skin were not upregulated in $TSLPR^{-/-}$ and neutrophil-depleted skin. For example, *Il33* upregulation is both neutrophil- and TSLPR-dependent (Figure 4A, Figure 4-Figure Supplement 1A). By contrast, upregulation of epithelial-derived cytokines and chemokines *Tslp*, *Cxcl1*, *Cxcl2*, *Cxcl3*, and *Cxcl5* was unaffected by either loss of TSLPR or neutrophil depletion (Figure 4B), suggesting these molecules are produced by skin cells even

when the MC903-evoked immune response is compromised. Consistent with previous studies, *Il4* upregulation was completely dependent on TSLPR but not neutrophils, establishing a role for TSLP signaling in the Type 2 immune response. Among the hundreds of MC903-dependent genes we examined, only a handful of genes were uniquely affected by neutrophil depletion. One such gene was *Cxcl10*, a chemokine known to be released by skin epithelial cells, neutrophils, and other myeloid cells.[52,69–74] *Cxcl10* expression was increased in TSLPR$^{-/-}$ but not neutrophil-depleted skin (Figure 4B, Figure 4-Figure Supplement 1A). CXCL10 has been previously shown to drive acute itch in a model of allergic contact dermatitis via CXCR3 signaling in sensory neurons,[75] and is elevated in skin of AD patients.[49] Expression of *Cxcl9* and *Cxcl11*, two other CXCR3 ligands that are elevated in AD but have an unknown role in itch, was also decreased in AD skin of neutrophil-depleted mice (Figure 4B).

CXCR3 signaling is necessary for MC903-evoked chronic itch

We hypothesized that neutrophil-dependent upregulation of CXCL10 activates sensory neurons to drive itch behaviors. Consistent with this model, neutrophil depletion attenuated the expression of activity-induced immediate early genes (*Vgf, Junb*) in the TG, suggestive of neutrophil-dependent sensory neuronal activity (Figure 4C, Figure 4-Figure Supplement 1B). We found that neutrophils also contributed to other sensory neuronal phenotypes in the model. For example, we observed that expression of *Lcn2*, a marker of neuropathic itch, and activity-induced genes *Fos* and *Junb* were not increased in spinal cord isolated from neutrophil-depleted animals, indicating that neutrophil-dependent scratching behaviors may indeed drive changes in the CNS (Figure 4D). We also observed that neutrophil-depleted animals displayed no skin hyperinnervation at day two (Figure 4E). This result was surprising because we did not observe significant neutrophil infiltration at this early time point, but these data suggest that low numbers of skin neutrophils are sufficient to mediate these early effects.

To test our model wherein CXCL10 activates CXCR3 to drive neutrophil-dependent itch, we first asked whether this CXCR3 ligand is in fact released in MC903-treated skin. We performed ELISA on cheek skin homogenate and found that CXCL10 protein was increased in MC903-treated skin from uninjected wild-type and TSLPR$^{-/-}$ animals, but not in skin from neutrophil-depleted mice (Figure 4F). To test whether CXCR3 signaling directly contributes to AD itch, we asked whether acute blockade of CXCR3 using the antagonist AMG 487[75] affected scratching behaviors in the MC903 model. We found that the CXCR3 antagonist strongly attenuated scratching behaviors on days five, eight, and twelve (Figure 4G), with the greatest effect at day eight. In contrast, CXCR3 blockade did not attenuate scratching behaviors in naive mice injected with the pruritogen chloroquine (Figure 4G), demonstrating that CXCR3 signaling contributes to chronic itch but is not required for scratching in response to an acute pruritogen. Thus, we propose that neutrophils promote chronic itch in atopic dermatitis via upregulation of CXCL10 and subsequent activation of CXCR3-dependent itch pathways (Figure 5).

Discussion

There is great interest in unraveling the neuroimmune interactions that promote acute and chronic itch. Here, we show that neutrophils are essential for the early development of MC903-evoked itch. We further show that the recruitment of neutrophils to the skin is sufficient to drive itch behaviors within minutes of infiltration. While neutrophils are known to release a variety of pruritogens, their roles in itch and AD were not studied.[52] Only a few studies have even reported the presence of neutrophils in human AD lesions.[12,76–78] Neutrophils have been implicated in psoriatic inflammation and inflammatory pain,[79–86] where they are thought to rapidly respond to tissue injury and inflammation,[87] but they have not been directly linked to itch.

There is a strong precedence for immune cell-neuronal interactions that drive modality-specific outcomes, such as itch versus pain, under distinct inflammatory conditions. In allergy, mast cells infiltrate the upper dermis and epidermis and release pruritogens to cause itch,[67,88] whereas in tissue injury, mast cell activation can trigger pain hypersensitivity.[89] Likewise, neutrophils are also implicated in both pain and itch. For example, pyoderma gangrenosum, which causes painful skin ulcerations recruits neutrophils to the deep dermal layers to promote tissue damage and pain.[52] In AD, neutrophils are recruited to the upper dermis and epidermis,[12,78] and we now show that neutrophils trigger itch in AD. Adding to the complex and diverse roles of neutrophils, neutrophils recruited to subcutaneous sites during invasive streptococcal infection alleviate pain by clearing the tissue of bacteria.[90] Several potential mechanisms may explain these diverse effects of neutrophils. First, the location of the inflammatory insult could promote preferential engagement of pain versus itch nerve fibers.[52] This is supported by observations that neutrophil-derived reactive oxygen species and leukotrienes can promote either itch or pain under different inflammatory conditions.[91–94] Second, it has been proposed that there are distinct functional subsets of neutrophils that release modality-specific inflammatory mediators.[95] Third, the disease-specific inflammatory milieu may induce neutrophils to specifically secrete mediators of either itch or pain. Indeed, all three of these mechanisms have been proposed to underlie the diverse functions of microglia and macrophages in homeostasis, tissue repair, injury, and neurodegenerative disease.[96] It will be of great interest to the field to decipher the distinct mechanisms by which neutrophils and other immune cells interact with the nervous system to drive pain and itch.

In addition to neutrophils, TSLP signaling and the Type 2 immune response plays an important role in the development of itch in the second week of the MC903 model. Dendritic cells, mast cells, basophils, and $CD4^+$ T cells are all major effectors of the TSLP inflammatory pathway in the skin. We propose that neutrophils play an early role in triggering itch and also contribute to chronic itch in parallel with the TSLP-Type 2 response. While we have ruled out an early role for TSLP signaling and basophils and $CD4^+$ T cells in early itch, other cell types such as mast cells, which have recently been linked directly to chronic itch,[67,88] and dendritic cells may be playing an important role in setting the stage for itch and inflammation prior to infiltration of neutrophils.

Given the large magnitude of the itch deficit in the neutrophil-depleted mice, we were surprised to find fewer expression differences in MC903-dependent, AD-associated genes between neutrophil depleted and non-depleted mice than were observed between WT and $TSLPR^{-/-}$ mice. One of the few exceptions were the Th1-associated genes *Cxcl9/10/11*.[11,97] We found that induction of these genes and of CXCL10 protein was completely dependent on neutrophils. While our results do not identify the particular cell type(s) responsible for neutrophil-dependent CXCL10 production, a number of cell types present in skin have been shown to produce CXCL10, including epithelial keratinocytes, myeloid cells, and sensory neurons.[52,69–74] In support of a role for neutrophils in promoting chronic itch, we observed striking differences in neutrophil-dependent gene expression in the spinal cord, where expression of activity-induced genes and the chronic itch gene *Lcn2* were markedly attenuated by loss of neutrophils. Moreover, we also demonstrate that depletion of neutrophils in the second week of the MC903 model can attenuate chronic itch-evoked scratching. In examining previous characterizations of both human and mouse models of AD and related chronic itch disorders, several studies report that neutrophils and/or neutrophil chemokines are indeed present in chronic lesions.[11–16,98–102] Our observations newly implicate neutrophils in setting the stage for the acute-to-chronic itch transition by triggering molecular changes necessary to develop a chronic, itchy lesion and also contributing to persistent itch.

Additionally, we demonstrate a novel role of CXCR3 signaling in MC903-induced itch. The CXCR3 ligand CXCL10 contributes to mouse models of acute and allergic itch;[75,103,104] however, its role in chronic itch was previously unknown. We speculate that the residual itch behaviors after administration of the CXCR3 antagonist could be due to TSLPR-dependent IL-4 signaling, as TSLPR-deficient mice display reduced itch behaviors by the second week of the model, or due to some other aspect of neutrophil signaling, such as release of proteases, leukotrienes, prostaglandins, or reactive oxygen species, all of which can directly trigger itch via activation of somatosensory neurons.[52] Our observations are in alignment with a recent study showing that dupilumab, a new AD drug that blocks IL4Rα, a major downstream effector of the TSLP signaling pathway, does not significantly reduce CXCL10 protein levels in human AD lesions.[105] Taken together, these findings suggest that the TSLP/IL-4 and neutrophil/CXCL10 pathways are not highly interdependent, and supports our findings that *Il4* transcript is robustly upregulated in the absence of neutrophils. Additionally, targeting IL4Rα signaling has been successful in treating itch and inflammation in some, but not all, AD patients.[106] We propose that biologics or compounds targeting neutrophils and/or the CXCR3 pathway may be useful for AD that is incompletely cleared by dupilumab monotherapy. Drugs targeting neutrophils are currently in clinical trials for the treatment of psoriasis, asthma, and other inflammatory disorders. For example, MDX-1100, a biologic that targets CXCL10, has already shown efficacy for treatment of rheumatoid arthritis in phase II clinical trials.[107] While rheumatoid arthritis and AD have distinct etiologies,[108] our body of work indicates that CXCL10 or CXCR3 may be promising targets for treating chronic itch. Our findings may also be applicable to other itch disorders where neutrophil chemoattractants and/or CXCL10 are also elevated, such as psoriasis and allergic contact dermatitis. Overall, our data suggest that neutrophils incite itch and inflammation in early AD through several mechanisms, including: 1) directly triggering itch upon infiltration into the skin, as shown by acute injection of CXCL1, and, 2) indirectly triggering itch by altering expression of endogenous pruritogens (e.g. induction of *Cxcl10* expression[52,69–74]). Together, these direct and indirect mechanisms for neutrophil-dependent itch may explain why neutrophils have a dramatic effect on scratching behaviors on not only days eight and twelve but also day five of the model, when neutrophils are recruited in large numbers, but CXCR3 ligands are not as robustly induced.

More generally, our study provides a framework for understanding how and when human chronic itch disease genes contribute to the distinct stages of AD pathogenesis. Our analysis of MC903-evoked transcriptional changes suggests we may be able to extend findings in the model not only to atopic dermatitis, but also to related disorders, including specific genetic forms of atopy. For example, we provide evidence that MC903 treatment may also model the filaggrin loss-of-function mutations, which are a key inciting factor in human heritable atopic disease.[45,46] There are many rich datasets looking at mature patient lesions and datasets for mature lesions in other mouse models of chronic itch.[11–13,15,16,22,101,109] Our study adds a temporal frame of reference to these existing datasets and sets the stage for probing the function of AD disease genes in greater detail. Furthermore, we have mapped the time course of gene expression changes in primary sensory ganglia and spinal cord during chronic itch development. We show that the MC903 model recapitulates several hallmarks of neuropathic disease on a time course much shorter than has been reported for chronic itch, or chronic pain. Nervous system tissues are extremely difficult to obtain from human AD patients, and thus little is known regarding the neuronal changes in chronic itch disorders in both mouse models and human patients. Our findings can now be compared to existing and future datasets examining neuronal changes in chronic pain, diabetic neuropathy, shingles, neuropathic itch, psoriasis, and other inflammatory disorders where neuronal changes are poorly understood but may contribute to disease progression. The early changes we see in skin innervation, sensory ganglia, and spinal cord dovetail with recent studies examining neuroimmune interactions in other inflammatory

conditions,[90,110–112] which all implicate early involvement of sensory neurons in the pathogenesis of inflammatory diseases.

Figure 1. The MC903 model parallels the progression of human atopic disease and suggests a temporal sequence of AD pathogenesis. **A.** Exact permutation test (10,000 iterations, see Methods) for significance of mean absolute $\log_2$ fold change in gene expression at Day 8 (MC903 vs. ethanol) of custom-defined groups of genes for indicated categories (see **Figure 1-source data 1**). **B.** Log_2 fold change in gene expression (MC903 vs. ethanol) in mouse skin at indicated time points for key immune and mouse/human AD genes that were significantly differentially expressed for at least one time point in the MC903 model. Only genes from our initial list (see Methods) differentially expressed at corrected $p < 0.05$ and changing > 2-fold between treatments for at least one condition are shown. Green bars = increased expression in MC903 relative to ethanol; magenta = decreased expression. Exact values and corrected *p*-values are reported in **Figure 1-source data 2** and **Supplemental Data**, respectively. D1 = 6 hours post-treatment; D2 = Day 2; D5 = Day 5; D8 = Day 8. **C.** Scratching behavior of mice treated with MC903 or ethanol for indicated length of time (two-way ANOVA: ****$p_{\text{interaction}} < 0.0001$, F(2,409) = 13.25; Sidak's multiple comparisons: $p_{day\ 3} = 0.1309$, n=62,51 mice; *$p_{day\ 5} = 0.0171$, n=69,56 mice; ****$p_{day\ 8} < 0.0001$, n=92,85 mice). Exact values displayed in **Figure 1-source data 3**. **D.** Log_2 fold change in gene expression of neutrophil chemoattractants (upper), Th2 cytokines (middle) and T cell chemoattractants (lower, from RNA-seq data). **E.** Neutrophil counts in MC903- and ethanol-treated skin at indicated time points (two-way ANOVA: **$p_{\text{treatment}} = 0.0023$, F(1,102) = 9.82; Sidak's multiple comparisons: $p_{day\ 2} > 0.999$, n=4,4 mice; $p_{day\ 3} = 0.9801$, n=5,5 mice; ***$p_{day\ 5} = 0.0003$, n=6,8 mice; ***$p_{day\ 8} = 0.0001$, n=40,38 mice). **F.** Basophil counts in MC903- and ethanol-treated skin at indicated time points (two-way ANOVA: **$p_{\text{treatment}} = 0.0051$, F(1,102) = 8.17; Sidak's multiple comparisons: $p_{day\ 2} > 0.999$, n=4,4 mice; $p_{day\ 3} = 0.8850$, n=5,5 mice; $p_{day\ 5} = 0.0606$, n=6,8 mice; ****$p_{day\ 8} < 0.0001$, n=40,38 mice). **G.** $CD4^+$ T cell counts in MC903- and ethanol-treated skin at indicated time points (two-way ANOVA: **$p_{\text{time}} = 0.0042$, F(1,44) = 9.10; $p_{day\ 3} = 0.9998$, n=8,6 mice; $p_{day\ 5} = 0.2223$, n=9,8 mice; **$p_{day\ 8} = 0.0021$, n=11,8 mice). Day 8 immune cell infiltrate represented as % of $CD45^+$ cells in **Figure 1-Figure Supplement 2A-B** (see **Supplementary Table 3** for all experimental conditions). Exact values displayed in **Figure 1-source data 4** and representative FACS plots for myeloid and T cell gating shown in **Figure 1-Figure Supplement 3A** and **Figure 1-Figure Supplement 4A**. For Figure 4E-G, data from mice receiving i.p. injection of PBS (see Figure 4) in addition to MC903 or EtOH are also included. **H.** (Upper and Lower) Representative maximum intensity Z-projections from immunohistochemistry (IHC) of whole-mount mouse skin on Day 2 of the MC903 model. Skin was stained with neuronal marker beta-tubulin III (BTIII; green). Hair follicle autofluorescence is visible in the magenta channel. Images were acquired on a confocal using a 20x water objective. **I.** Quantification of innervation (see Methods) of mouse skin as determined from BTIII staining (*p = 0.012; two-tailed t-test (t =3.114; df =9); n = 7,4 images each from 2 mice per treatment). Day 1 IHC results as follows: 31.78 ± 18.39 % (MC903) and 31.51 ± 16.43 % (EtOH); p = 0.988; two-tailed unpaired t-test; n = 6 images each from 2 mice per treatment. Exact values are reported in **Figure 1-source data 5**. **J.** Quantification of $CGRP^+$ nerve fibers (see Methods) in skin (**p = 0.0083; two-tailed t-test (t =2.868; df =25); n=15, 12 images from 3 mice per treatment). Exact values are reported in **Figure 1-source data 5**. Representative images in **Figure 1-Figure Supplement 9A**.

Figure 1-Figure Supplement 1. Expression of mouse and human itch genes. A. Log_2 fold change in gene expression (MC903 vs. ethanol) in mouse skin at indicated time points for genes implicated in mouse or human acute or chronic itch that were significantly differentially expressed for at least one time point in the MC903 model. Green bars = increased expression

in MC903 relative to ethanol; magenta = decreased expression. Exact values and corrected *p*-values are reported in **Figure 1-source data 6** and **Supplemental Data**, respectively.

Figure 1-Figure Supplement 2. Immune cells represented as % of CD45$^+$ cells. A. Number of CD45$^+$ cells in MC903-treated skin on days 2-8 of the model. **B.** Skin-infiltrating immune cell subtypes on days 2-8 of the MC903 model shown in **Figure 1**, represented as % of CD45$^+$ cells. CD4$^+$ T cell measurements were acquired using a separate staining panel from different animals than the myeloid cell measurements (see Methods) and were not included. See **Supplementary Table 3** for % of CD45$^+$ cell measurements for all flow cytometry experiments. Error bars represent mean ± SEM.

Figure 1-Figure Supplement 3. Myeloid and granulocyte gating strategy. A-C. Representative FACS plots of cells isolated from MC903-treated cheek skin showing gating strategy for neutrophils (A), inflammatory monocytes (A), mast cells (B), basophils (B), and eosinophils (C) as shown in **Figure 1E-F** and **Figure 1-Figure Supplement 5**.

Figure 1-Figure Supplement 4. T cell gating strategy. A. Representative FACS plots of cells isolated from MC903-treated cheek skin showing gating strategy for CD4$^+$ T cells as shown in **Figure 1G**.

Figure 1-Figure Supplement 5. Immune cell counts in MC903-treated skin. A. Inflammatory monocyte counts in MC903- and ethanol-treated skin at indicated time points (two-way ANOVA: $p_{\text{treatment}}$= 0.0662, F(1,102) = 3.44; n=4,4,5,5,6,8,40,38 mice). **B.** Mast cell counts in MC903- and ethanol-treated skin at indicated time points (two-way ANOVA: **$p_{\text{treatment}}$= 0.0024, F(1,102) = 9.69; Sidak's multiple comparisons: $p_{day\ 2}$ > 0.999, n=4,4 mice; $p_{day\ 3}$ = 0.3019, n=5,5 mice; $p_{day\ 5}$ = 0.0586, n=6,8 mice; ****$p_{day\ 8}$ < 0.0001, n=40,38 mice). **C.** Eosinophil counts in MC903- and ethanol-treated skin at indicated time points (two-way ANOVA: p_{time}= 0.0471, F(3,102) = 2.74; Sidak's multiple comparisons: $p_{day\ 2}$ > 0.999, n=4,4 mice; $p_{day\ 3}$ = 0.3596, n=5,5 mice; $p_{day\ 5}$ = 0.9998, n=6,8 mice; **$p_{day\ 8}$ = 0.0020, n=40,38 mice). Data from mice receiving i.p. injection of PBS (see Figure 4) in addition to MC903 or EtOH are also included. Exact values displayed in **Figure 1-source data 4**.

Figure 1-Figure Supplement 6. Protease receptor activation triggers rapid upregulation of neutrophil chemoattractant genes in human keratinocytes. A. Heat map showing $\log_2$ fold change in gene expression in cultured human keratinocytes 3 hours after SLIGRL treatment (100 μM; bottom; see **Figure 1-source data 7**) compared to vehicle controls, as measured by RNA-seq. Genes are sorted by descending corrected *p*-value; only significantly differentially expressed ($p < 0.05$) are displayed. Exact values and corrected *p*-values are reported in **Figure 1-source data 7** and **Supplemental Data**, respectively.

Figure 1-Figure Supplement 7. Expression of neuronal genes and axon guidance molecules in skin. A. Log_2 fold change in gene expression (MC903 vs. EtOH) in mouse skin at indicated time points for markers of locally translated sensory neuronal transcripts or genes implicated in neurite remodeling and/or axon guidance that were significantly differentially expressed for at least one time point in the MC903 model. Green bars = increased expression in MC903 relative to ethanol; magenta = decreased expression. Exact values and corrected *p*-values are reported in **Figure 1-source data 8** and **Supplemental Data**, respectively.

Figure 1-Figure Supplement 8. Method of image quantification for whole mount skin. **A.** Representative maximum intensity z-projection of beta tubulin III staining in cheek skin. **B.**

506 Binary image after edge-detection. **C.** % Area innervated was calculated from the percentage of
507 the image area which was occupied by the regions of interest (ROIs) outlined in red.
508
509 **Figure 1-Figure Supplement 9. Peptidergic fibers display hyperinnervation in MC903-**
510 **treated skin. A.** Representative maximum intensity Z-projections from immunohistochemistry
511 (IHC) of whole-mount mouse skin on day 2 of the MC903 model. Skin was stained with
512 peptidergic neuronal marker Calcitonin related-gene peptide (CGRP; white). Images were
513 acquired on a confocal microscope using a 20x water objective.
514
515 **Figure 1-Figure Supplement 10. Inflammatory lipids in MC903-treated skin. A.**
516 Quantification of indicated lipids from 6 mm biopsy punches of cheek skin of MC903- and EtOH-
517 treated mice (at day 8) by LC-MS/MS (**p = 0.006 (t=4.148,df=6), *p = 0.024 (t=3.003,df=6),
518 ***p = 0.0007 (t=6.392,df=6), *p = 0.022 (t=3.058,df=6); two-tailed unpaired t-tests; n = 4 mice
519 per group, see **Figure 1-source data 8**).
520
521 **Figure 1-source data 1.** Values displayed in the bar plot shown in Figure 1A.
522 **Figure 1-source data 2.** Values displayed in the heat map shown in Figure 1B.
523 **Figure 1-source data 3**. Values displayed in the bar plot shown in Figure 1C.
524 **Figure 1-source data 4.** Values displayed in the bar plots shown in Figure 1E-G and Figure 1-
525 Figure Supplement 5A-C.
526 **Figure 1-source data 5.** Values displayed in the bar plots shown in Figure 1I and Figure 1J.
527 **Figure 1-source data 6.** Values displayed in the heat map shown in Figure1-Figure
528 Supplement 1A.
529 **Figure 1-source data 7.** Values displayed in the heat map shown in Figure1-Figure
530 Supplement 6A.
531 **Figure 1-source data 8.** Values displayed in the heat map shown in Figure1-Figure
532 Supplement 7A.
533 **Figure 1-source data 9.** Values displayed in the bar plot shown in Figure1-Figure Supplement
534 10A.
535
536 **Supplementary Table 1.** Number of mapped reads and sample information for all RNA-seq
537 samples represented in the manuscript.
538
539 **Supplementary Table 2.** Outputs of statistical tests performed on behavioral and flow
540 cytometry data to determine whether select data sets could be combined.
541
542 **Supplementary Table 3**. All flow cytometry data from Figures 1-2 represented as % of $CD45^+$
543 cells.
544
545 **Supplemental Data.** DESeq differential expression output tables for all RNA-seq experiments
546 in the manuscript.
547

Figure 2. Neutrophils are necessary and sufficient for itch behaviors. A. Scratching behavior of uninjected and PBS-injected mice (combined) and aGr1-injected mice treated with MC903 or ethanol for indicated length of time (two-way ANOVA: ****$p_{interaction}$ < 0.0001, F(4,447) = 7.16; Tukey's multiple comparisons: $p_{day\ 3\ MC903\ vs.\ EtOH}$ = 0.1111 n=62,51,17 mice; *$p_{day\ 5\ MC903\ vs.\ EtOH}$ = 0.0154, $p_{day\ 5\ MC903\ vs.\ aGr1}$ =0.9854, $p_{day\ 5\ aGr1\ vs.\ EtOH}$ =0.2267, n=69,56,17 mice; ****$p_{day\ 8\ MC903\ vs.\ EtOH}$ < 0.0001, ***$p_{day\ 8\ MC903\ vs.\ aGr1}$ = 0.0007, $p_{day\ 8\ aGr1\ vs.\ EtOH}$ = 0.1543, n=92,85,17 mice). **B.** Neutrophil count from cheek skin of uninjected/PBS-injected MC903- and ethanol-treated, and aGr1-injected MC903-treated mice on day 8 (one-way ANOVA: ****p < 0.0001, F(2,92) = 10.59; Tukey's multiple comparisons: ****$p_{MC903\ vs.\ EtOH}$ < 0.00001, n=40,38 mice; *$p_{MC903\ vs.\ aGr1\ MC903}$ = 0.0109, n=40,17 mice; $p_{aGr1\ vs.\ EtOH}$ = 0.8859, n=38,17 mice). **C.** Basophil count from cheek skin of uninjected/PBS-injected MC903- and ethanol-treated, and aGr1-injected MC903-treated mice on day 8 (one-way ANOVA: ****p = 0.0001, F(2,92) = 14.61; Tukey's multiple comparisons: $p_{MC903\ vs.\ aGr1\ MC903}$ = 0.3217, n=40,17 mice, ****$p_{MC903\ vs.\ EtOH}$ < 0.0001, n=40,38 mice, *$p_{aGr1\ MC903\ vs.\ EtOH}$ = 0.0204, n=17,38 mice). **D.** $CD4^+$ T cell count from cheek skin of PBS-injected MC903- and ethanol-treated, and aGr1-injected MC903-treated mice on day 8 (two-way ANOVA: **$p_{treatment}$ = 0.0035, F(1,35) = 9.82; Holm-Sidak multiple comparisons for PBS versus aGr1: p_{MC903} = 0.8878, n=9,11 mice; p_{EtOH} = 0.5201, n=8,9 mice). Control MC903 and EtOH data from **Figure 2B-C** are also displayed in **Figure 1**. Exact values displayed for **Figure 2A-D** in **Figure 2-source data 1**. **E.** Scratching behavior of mice immediately after injection of 1 µg CXCL1 or PBS (s.c. cheek). For neutrophil-depletion experiments, mice received 250 µg anti-Gr1 (aGr1) 20 hours prior to cheek injection of CXCL1 or PBS (one-way ANOVA: ****p < 0.0001, F(4,88) = 75.53; Tukey's multiple comparisons: *$p_{CXCL1\ vs.\ PBS}$ = 0.0126, n=36,31 mice; $p_{aGr1\text{-}CXCL1\ vs.\ aGr1\text{-}PBS}$ > 0.9999, n=10,10 mice; $p_{aGr1\text{-}CXCL1\ vs.\ PBS}$ = 0.9986, n=10,31 mice). Exact values displayed in **Figure 2-source data 2**. **F.** Scratching behavior of WT and $TSLPR^{-/-}$ (TSLPR KO) mice treated with MC903 or ethanol for indicated length of time (two-way ANOVA: ****$p_{interaction}$ < 0.0001, F(9,657) = 4.93; Tukey's multiple comparisons: ****$p_{day\ 8\ WT\ MC903\ vs.\ EtOH}$ < 0.0001, *$p_{day\ 8\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.0194, **$p_{day\ 8\ KO\ MC903\ vs.\ KO\ EtOH}$ = 0.0039, n=92,85,36,26 mice; ****$p_{day\ 12\ WT\ MC903\ vs.\ EtOH}$ < 0.0001, **$p_{day\ 12\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.0028, $p_{day\ 12\ KO\ MC903\ vs.\ KO\ EtOH}$ = 0.7061, n=26,26,27,23 mice). **G.** Neutrophil count from cheek skin of wild-type MC903- and ethanol-treated, and $TSLPR^{-/-}$ MC903-treated mice on day 5 (two-way ANOVA: **$p_{genotype}$ = 0.0025, F(2,125) = 6.28; Tukey's multiple comparisons: ****$p_{day\ 5\ WT\ MC903\ vs.\ WT\ EtOH}$ < 0.0001, n=6,8 mice; $p_{day\ 5\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.2198, n=6,6 mice; *$p_{day\ 5\ WT\ EtOH\ vs.\ KO\ MC903}$ = 0.0212, n=8,6 mice). **H.** Basophil count from cheek skin of wild-type MC903- and ethanol-treated, and $TSLPR^{-/-}$ MC903-treated mice on day 8 (two-way ANOVA: **$p_{genotype}$ = 0.0003, F(2,117) = 8.87; Tukey's multiple comparisons: ****$p_{day\ 8\ WT\ MC903\ vs.\ WT\ EtOH}$ < 0.0001, n=40,38 mice; ****$p_{day\ 8\ WT\ MC903\ vs.\ KO\ MC903}$ < 0.0001, n=40,15 mice; $p_{day\ 8\ WT\ EtOH\ vs.\ KO\ MC903}$ = 0.9519, n=38,15 mice). See also **Figure 2-Figure Supplement 5A**. For **Figures 2G-H**, data from days 3, 5, and 8 are presented in **Figure 2-source data 3. I.** $CD4^+$ T cell count from cheek skin of wild-type MC903- and ethanol-treated, and $TSLPR^{-/-}$ MC903-treated mice on day 8 (one-way ANOVA: **p = 0.0053, F(2,24) = 6.564; Tukey's multiple comparisons: *$p_{WT\ MC903\ vs.\ WT\ EtOH}$ = 0.0163, n=11,8 mice; *$p_{MC903\ vs.\ KO\ MC903}$ = 0.0130, n=11,8 mice; $p_{WT\ EtOH\ vs.\ KO\ MC903}$ = 0.9953, n=8,8 mice). Wild-type MC903 and EtOH data from **2F-H** are also displayed in **Figure 1**. Exact values for **Figure 2F-I** displayed in **Figure 2-source data 3**. **J.** Neutrophil count from cheek skin of wild-type MC903- and ethanol-treated mice on day 12 of the MC903 model. MC903-treated animals received daily i.p. injections of 250 µg aGr1 antibody or PBS (250 µL) on days 8-11 of the model (one-way ANOVA: *p = 0.01, F(2,13) = 6.69; Tukey's multiple comparisons: *$p_{MC903\text{-}PBS\ vs.\ EtOH}$ = 0.0141, n=6,5 mice; *$p_{MC903\text{-}PBS\ vs.\ MC903\text{-}aGr1}$ = 0.10330, n=6,5 mice; $p_{MC903\text{-}aGr1\ vs.\ EtOH}$ = 0.9005, n=5,5 mice). **K.** Time spent scratching over a thirty minute interval for wild-type MC903- and ethanol-treated mice on day 12 of the MC903 model. MC903-treated animals received daily i.p. injections of 250 µg aGr1 antibody or PBS (250 µL) on days 8-11 of the model (one-way ANOVA: ****p < 0.0001, F(2,26) = 53.1; Tukey's multiple comparisons: ****$p_{MC903\text{-}PBS\ vs.\ EtOH}$ <

599 0.0001, n=12,5 mice; ****$p_{MC903\text{-}PBS\ vs.\ MC903\text{-}aGr1}$ < 0.0001, n=12,12 mice; $p_{MC903\text{-}aGr1\ vs.\ EtOH}$ =
600 0.3734, n=12,5 mice). Values from bar plots are reported in **Figure 2-source data 5**.
601
602 **Figure 2-Figure Supplement 1. aGr1 treatment preferentially depletes neutrophils. A.**
603 Representative flow cytometry plots of cells collected from blood of mice injected with PBS or
604 aGr1 (250 µg, i.p.) once-daily for five days concurrent with daily MC903 topical treatment.
605 Shown are $CD45.2^+CD11b^+$ cells, plotted by Ly6G and Ly6C signal, with neutrophil (Neuts.) and
606 inflammatory monocyte (IMs) populations indicated. Neutrophils were defined as
607 $Cd11b^+Ly6G^+Ly6C^{mid/high}$ and IMs were defined as $Cd11b^+Ly6G^-Ly6C^{high}$ (see Methods). **B.**
608 Representative flow cytometry plot as in **A**, depicting neutrophil and IM populations from blood
609 collected on day 8. **C. (Left)** Neutrophil counts in blood shown as % of $Cd11b^+$ cells from
610 aGr1/MC903 (black triangles) and PBS/MC903 (gray circles)-treated animals on days 3, 5, and
611 8 of the model (two-way repeated measures ANOVA: ****$p_{treatment}$ < 0.0001, F(1,31) = 299.5;
612 Sidak's multiple comparisons: ****$p_{day\ 3}$ < 0.0001; ****$p_{day\ 5}$ < 0.0001; ****$p_{day\ 8}$ < 0.0001, n= 16,17
613 mice). **(Right)** Inflammatory monocyte counts in blood shown as % of $Cd11b^+$ cells from
614 aGr1/MC903 and PBS/MC903-treated animals on days 3, 5, and 8 of the model (two-way
615 repeated measures ANOVA: *$p_{treatment}$ = 0.0468, F(1,31) = 4.287; Sidak's multiple comparisons:
616 **$p_{day\ 3}$ = 0.0015; $p_{day\ 5}$ = 0.1918; $p_{day\ 8}$ = 0.2013, n= 16,17 mice). Exact values displayed in
617 **Figure 2-source data 4**.
618
619 **Figure 2-Figure Supplement 2. CXCL1 rapidly and selectively recruits neutrophils to skin.**
620 **A.** Representative flow cytometry plots of cells from cheek skin of mice injected with PBS or
621 CXCL1 (1 µg in 20 µL, s.c.). Shown are $CD45.2^+CD11b^+$ cells, plotted by Ly6G and Ly6C signal,
622 with neutrophil and inflammatory monocyte (IMs) populations indicated. **B.** Neutrophil count
623 from cheek skin of mice 5, 15, and 30 minutes after injection of CXCL1 or PBS (two-way
624 ANOVA: *$p_{interaction}$= 0.0239, F(2,21) = 4.48; Sidak's multiple comparisons: $p_{5\ min}$ > 0.9999, n=4,5
625 mice; *$p_{day\ 15\ min}$ = 0.0141, n=4,4 mice; **$p_{day\ 30\ min}$ = 0.0031, n=3,7 mice). Exact values displayed
626 in **Figure 2-source data 2**. **C.** Blood neutrophils as % of $Cd11b^+$ cells approximately 20 hours
627 after injection of 250 µg aGr1 (n=15 mice). Mice assayed for CXCL1-evoked itch behavior
628 immediately preceding blood isolation (see **Figure 2E**). Exact values displayed in **Figure 2-**
629 **source data 2**. See **Figure 2-Figure Supplement 1C** for representative blood neutrophil
630 measurements from PBS-injected animals.
631
632 **Figure 2-Figure Supplement 3. Neutrophil depletion does not affect chloroquine-evoked**
633 **itch. A.** Scratching behavior of mice immediately after injection of chloroquine (CQ) or PBS (s.c.
634 cheek). For neutrophil-depletion experiments, mice received 250 µg anti-Gr1 (aGr1) 20 hours
635 prior to cheek injection of CQ or PBS (two-tailed t-test: ****p < 0.0001 (t=10.58, df=14); n=6,10
636 mice). Exact values displayed in **Figure 2-source data 2**.
637
638 **Figure 2-Figure Supplement 4. Loss of TSLPR reduces skin basophil and mast cell**
639 **numbers in the first week of AD development. A.** Basophil count from cheek skin of wild-type
640 MC903- and ethanol-treated, and $TSLPR^{-/-}$ MC903-treated mice after 3 or 5 days of treatment
641 (two-way ANOVA: ***p_{time} = 0.0003, F(2,117) = 8.87; Tukey's multiple comparisons: $p_{day3\ WT\ MC903}$
642 $_{vs.\ KO\ MC903}$ = 0.6540, n=3,5 mice; *$p_{day\ 5\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.1023, n=6,6 mice; $p_{day\ 5\ WT\ EtOH\ vs.\ KO}$
643 $_{MC903}$ = 0.9077, n=8,6 mice; $p_{day\ 5\ WT\ MC903\ vs.\ WT\ EtOH}$ = 0.0264, n=6,8 mice). **B.** Mast cell count from
644 cheek skin of wild-type MC903- and ethanol-treated, and $TSLPR^{-/-}$ MC903-treated mice after 3,
645 5, or 8 days of treatment (two-way ANOVA: *$p_{genotype}$ = 0.0384, F(2,117) = 3.35; Tukey's multiple
646 comparisons: $p_{day\ 3\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.4133, n=3,5 mice; $p_{day\ 5\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.9882,
647 n=6,6 mice; *$p_{day\ 5\ WT\ MC903\ vs.\ WT\ EtOH}$ = 0.0440, n=6,5 mice; *$p_{day\ 5\ KO\ MC903\ vs.\ WT\ EtOH}$ = 0.0294, n=6,5
648 mice; *$p_{day\ 8\ WT\ MC903\ vs.\ KO\ MC903}$ = 0.0188, n=40,15 mice; ****$p_{day\ 8\ WT\ MC903\ vs.\ WT\ EtOH}$ < 0.0001,

649 n=40,38 mice; $p_{day\ 8\ WT\ EtOH\ vs.\ KO\ MC903}$ = 0.7810, n=38,15 mice). Data from days 3, 5, and 8 are
650 presented in **Figure 2-source data 3.**
651
652 **Figure 2-Figure Supplement 5. Neutrophils robustly infiltrate the skin in the DNFB mouse**
653 **model of atopic dermatitis. A.** Neutrophil count from ear skin of wild-type DNFB- and vehicle-
654 treated mice 24 hours after challenge with DNFB or vehicle performed five days after initial
655 DNFB sensitization on shaved rostral back skin (***p = 0.0004; two-tailed t-test (*t*=4.290; *df*
656 =18); n=10 mice per group). Values from bar plot is reported in **Figure 2-source data 6**.
657
658 **Figure 2-source data 1.** Values displayed in bar plots shown in Figure 2A-D.
659 **Figure 2-source data 2.** Values displayed in the bar plots shown in Figure 2E and Figs. 2-
660 Figure Supplement 2-3.
661 **Figure 2-source data 3.** Values displayed in the bar plots shown in Figure 2F-I and Figure 2-
662 Figure Supplement 4A-B.
663 **Figure 2-source data 4.** Values used to generate the line plots shown in Figure 2-Figure
664 Supplement 1C.
665 **Figure 2-source data 5.** Values displayed in the bar plots shown in Figure 2J-K.
666 **Figure 2-source data 6.** Values displayed in the bar plots in Figure 2-Figure Supplement 5A.

667 **Figure 3. The MC903 model induces rapid and robust changes in neuronal tissue. A.**
668 Exact permutation test (10,000 iterations, see Methods) for significance of mean absolute $\log_2$
669 fold change in gene expression at Day 8 (MC903 vs. ethanol) of custom-defined groups of
670 genes for indicated categories (see **Figure 3-source data 1**). **B.** Log_2 fold change in gene
671 expression (MC903 vs. ethanol) in mouse trigeminal ganglia (TG) at indicated time points for all
672 genes which were significantly differentially expressed for at least one time point in the MC903
673 model. Green bars = increased expression in MC903 relative to ethanol; magenta = decreased
674 expression. Exact values and corrected *p*-values are reported in **Figure 3-source data 2** and
675 **Supplemental Data**, respectively. **C**. Representative composite images showing immune cells
676 (CD45, green), and sensory neurons (Prph, magenta) with DAPI (blue) in sectioned trigeminal
677 ganglia from mice treated with Vehicle or MC903 for five days on the cheek. **D**. Quantification of
678 images examining average number of $CD45^+$ cells per section and average ratio of
679 CD45:Peripherin cells per section after five days of treatment (p = 0.562 (t=0.6318, df=4), 0.542
680 (t=0.6660, df=4); two-tailed unpaired t-tests, n=33-159 fields of view (images) each of both
681 trigeminal ganglia from 3 mice per condition treated bilaterally). **E.** Representative composite
682 images showing immune cells (CD45, green), and sensory neurons (Peripherin (Prph),
683 magenta) with DAPI (blue) in sectioned trigeminal ganglia from mice treated with Vehicle or
684 MC903 for eight days on the cheek. **F**. Quantification of images examining average number of
685 $CD45^+$ cells per section and average ratio of CD45:Peripherin cells per section after eight days
686 of treatment (**p = 0.0019 (t=5.977,df=5), **p = 0.0093 (t=4.107,df=4); two-tailed unpaired t-
687 tests; n=42-172 fields of view (images) each of both trigeminal ganglia from 3 EtOH or 4 MC903
688 animals treated bilaterally). Scale bar = 100 μm. Images were acquired on a fluorescence
689 microscope using a 10x air objective. Values from bar plots and all TG IHC data are available in
690 **Figure 3-source data 3**. **G.** Log_2 fold change in gene expression (MC903 vs. ethanol) in mouse
691 spinal cord on day 8 showing selected differentially expressed genes ($p_{adjusted} < 0.05$). Exact
692 values and corrected *p*-values are reported in **Supplemental Data**.
693
694 **Figure 3-Figure Supplement 1. Method of image quantification for sectioned trigeminal**
695 **ganglia**. **A.** Representative composite image showing CD45 (green), Peripherin (magenta), and
696 DAPI (blue). **B.** Single-channel CD45 image with automated min/max intensity thresholding. **C.**
697 Resultant binary image generated from **B. D.** Cells were counted as the number of regions of
698 interest (ROIs) outlined in blue.
699
700 **Figure 3-source data 1.** Values displayed in the bar plot shown in Figure 3A.
701 **Figure 3-source data 2.** Values displayed in the heat map shown in Figure 3B.
702 **Figure 3-source data 3.** Quantification of all IHC samples from trigeminal ganglia, and Values
703 displayed in the bar plots shown in Figure 3D,F.

Figure 4. Neutrophils are required for induction of the itch-inducing chemokine CXCL10. A. Log_2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from uninjected wild-type, aGR1-treated, and TSLPR$^{-/-}$ animals. **B.** Log_2 fold change (Day 8 MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, and TSLPR$^{-/-}$ animals. **C.** Log_2 fold change (Day 8 MC903 vs. EtOH) of activity-induced genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR$^{-/-}$ animals. **D.** Log_2 fold change (Day 8 MC903 vs. EtOH) of *Lcn2* and activity-induced genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. For **Figure 4A-D**, exact values and corrected *p*-values are reported in **Supplemental Data. E.** Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as determined from BTIII staining (p = 0.8985; two-tailed t-test (t =0.1294; df =18); n = 9,11 images each from 2 mice per treatment. Exact values are reported in **Figure 4-source data 1**. **F.** CXCL10 levels in skin homogenate as measured by ELISA on day 8 of the MC903 model for uninjected animals (left; *p = 0.029 (t=2.715, df=7); two-tailed t-test; n = 4,5 animals), animals which received aGr1 for 8 days (middle; p = 0.43 (t=0.815, df=11); two-tailed t-test; n = 6,6 animals), and TSLPR$^{-/-}$ animals (right; *p = 0.0357 (t=2.696, df=6); two-tailed t-test; n = 4,4 animals. Skin homogenates were isolated on separate days and so uninjected, WT samples were not compared to aGr1-treated samples or to TSLPR$^{-/-}$ samples. **G.** (Left) Time spent scratching over a thirty minute interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back); (two-way ANOVA: ****$p_{treatment}$ < 0.0001, F(1,67) = 50.64; Tukey's multiple comparisons: *$p_{day\ 5}$ = 0.0216, n=8,10 mice; ***$p_{day\ 8}$ = 0.0007, n=18,21 mice; ****$p_{day\ 12}$ < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (20% HPCD in PBS; 50 µL s.c. in rostral back), and immediately after mice were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 (t=0.0964, df=8); two-tailed t-test; n = 5,5 mice. Values from bar plots in **Figures 4F-G** are displayed in **Figure 4-source data 2**.

Figure 4-Figure Supplement 1. MC903-dependent gene expression changes in aGr1-treated and TSLPR$^{-/-}$ animals. A. Heat map showing log_2 fold change in gene expression (Day 8 MC903 vs. EtOH) for itch-associated genes in wild-type, aGr1-treated, and TSLPR$^{-/-}$ skin. Green bars = increased expression in MC903 relative to ethanol; magenta = decreased expression. Exact values and corrected *p*-values are reported in **Figure 4-source data 3** and **Supplemental Data**, respectively. **B.** Heat map showing log_2 fold change in gene expression (Day 8 MC903 vs. EtOH) for wild-type, aGr1-treated, and TSLPR$^{-/-}$ mouse trigeminal ganglia (TG) at indicated time points for all genes which were significantly differentially expressed for at least one time point in the MC903 model (See **Figure 2D**). Green bars = increased expression in MC903 relative to ethanol; magenta = decreased expression. Exact values and corrected *p*-values are reported in **Figure 4-source data 4** and **Supplemental Data**, respectively.

Figure 4-source data 1. Values displayed in the bar plot shown in Figure 4E.
Figure 4-source data 2. Values displayed in the bar plots shown in Figure 4F-G.
Figure 4-source data 3. Values displayed in the heat map shown in Figure 4-Figure Supplement 1A.
Figure 4-source data 4. Values displayed in the heat map shown in Figure 4-Figure Supplement 1B.

751 **Figure 5. Model of early AD pathogenesis. A.** AD induction first results in increased protease
752 expression and barrier dysfunction, which drives production of the cytokines TSLP and CXCL1
753 via PAR2 activation within keratinocytes. CXCL1 can recruit neutrophils via its receptor CXCR2.
754 Neutrophils may evoke itch by multiple pathways, including degranulation and release of
755 proteases and histamine, production of sensitizing lipids such as PGE_2 and LTB_4,[52] and
756 induction of CXCL10 expression, which can activate sensory neurons via CXCR3. TSLP
757 activates a number of immune cells to elicit IL-4 production, including basophils, which results in
758 increased IL-4, recruitment of $CD4^+$ T cells,[22] and sensitization of neurons to promote itch later
759 in the model.
760
761 **Supplementary Data** - The outputs of all differential expression analyses used to determine
762 adjusted *p* value and $\log_2$ fold change for RNA-seq experiments.
763

764 **Methods**

Key Resources Table				
Reagent type (species) or resource	**Designation**	**Source or reference**	**Identifiers**	**Additional information**
strain, strain background(C57BL/6J)	C57BL/6; WT; wild-type	The Jackson Laboratory	Jackson Stock #: 000664; RRID:IMSR_JAX:000664	
strain, strain background(C57BL/6NCrl)	C57BL/6; WT; wild-type	Charles River Laboratories	RRID:IMSR_CRL:27; Charles River strain code #: 027;	
strain, strain background(Crlf2tm1Jni)	Crlf2tm1Jni; TSLPR KO	PMID:14993294	RRID:MGI:3039553; MGI Cat# 3039553	Obtained from the laboratory of Steven F. Ziegler (Ben Aroya Research Institute)
antibody(Purified anti-mouse Ly-6G/Gr-1 antibody. Low endotoxin, no azide, in PBS)	anti-GR1 (RB6-8C5); aGr1	UCSF Core	UCSF Core Cat# AM051	Obtained from the laboratory of Daniel Portnoy (UC Berkeley)
antibody(LEAF Purified anti-mouse Ly-6G/Ly-6C (Gr-1) antibody)	LEAF Purified anti-mouse Ly-6G/Ly-6C (Gr-1) antibody; RB6-8C5; aGr1	Biolegend	RRID:AB_313379; BioLegend Cat# 108414	
antibody (Rabbit polyclonal to β-tubulin III)	Rabbit anti-β-tubulin III	Abcam	RRID:AB_444319; Cat # ab18207	
antibody (Rabbit polyclonal to CGRP)	Rabbit anti-CGRP	Immunostar	RRID:AB_572217; Cat # 24112	
antibody(Chicken polyclonal to Peripherin)	Chicken anti-Peripherin	Abcam	RRID:AB_777207; Cat # ab39374	
antibody(Goat Anti-Mouse IgG H&L Alexa Fluor 488)	Goat anti-Mouse Alexa 488	Abcam	RRID:AB_2688012; Cat # ab150117	
antibody(Goat anti-Chicken IgY (H+L) Secondary Antibody, Alexa Fluor 488)	Goat anti-Chicken Alexa 488	ThermoFisher Scientific	RRID:AB_2534096; Cat # A-11039	
antibody(Goat Anti-Chicken IgG (H+L) Secondary Antibody, Alexa Fluor 594)	Goat anti-Chicken Alexa 594	ThermoFisher Scientific	RRID:AB_2534099; Cat # A11042	
antibody(Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor 594)	Goat anti-Rabbit Alexa 594	Invitrogen	RRID:AB_2556545; Cat # R37117	
commercial assay or kit(Promocell Keratinocyte Growth Medium 2)	Promocell Keratinocyte Growth Medium 2	Promocell	Cat # C-20011	
cell line(Normal Human Epidermal Keratinocytes (NHEK), single juvenile donor, cryopreserved)	Normal Human Epidermal Keratinocytes (NHEK)	Promocell	Cat # C-12001	
other(Liberase TM Research Grade)	Liberase	Roche	Cat # 5401119001	
other(Dnase I from bovine pancreas)	Dnase I	Sigma	Cat # 11284932001	

other(Ambion™ DNase I (RNase-free))	Ambion[a] DNase I (RNase-free); DNAse	Ambion	Cat # AM2222	
peptide, recombinant protein(SLIGRL-NH2)	SLIGRL	Tocris	Cas 171436-38-7 ; Cat #1468	
commercial assay or kit(RNeasy mini kit)	Qiagen RNeasy mini kit	Qiagen	Cat # 74104	
commercial assay or kit(RNAzol RT)	RNAzol	Sigma-Aldrich	Cat # R4533-50ML	
chemical compound, drug((2-Hydroxypropyl)-β-cyclodextrin)	HPCD	Sigma-Aldrich	Cas 128446-35-5; Cat # H107	
chemical compound, drug(Methyl alcohol)	Methanol; MeOH	Sigma-Aldrich	Cas 67-56-1; Cat # 34860	
chemical compound, drug(Ethyl alcohol)	Ethanol, Absolute (200 Proof), Molecular Biology Grade, Fisher BioReagents™; Absolute Ethanol, Molecular-Biology grade; Ethanol; EtOH	Fischer Scientific	Cas 64-17-5; Cat # BP2818100	
chemical compound, drug(Calcipotriol)	MC903; Calcipotriol	Tocris	Cas 112965-21-6; Cat # 2700	
chemical compound, drug((±)-AMG 487)	AMG-487; AMG	Tocris	Cas 947536-03-0; Cat # 4487	
chemical compound, drug(Chloroquine diphosphate)	Chloroquine	Sigma-Aldrich	CAS 50-63-5; Cat # C6628	
chemical compound, drug(Dimethyl sulfoxide)	DMSO	Sigma-Aldrich	Cat # 8418-100mL	
chemical compound, drug(Formaldehyde, 16%, methanol free, Ultra Pure)	Paraformaldehyde; PFA	Polysciences, Inc.	Cat # 18814-10	
chemical compound, drug(Tissue Tek Optimal cutting temperature compound (OCT))	OCT	Sakura Finetek USA	Cat # 4583	
chemical compound, drug(Triton X-100 solution)	Triton X-100	BioUltra	CAS 9002-93-1; Cat # 93443	
chemical compound, drug(Phosphate-buffered saline (PBS), pH 7.4)	PBS	Gibco	Cat # 10010023	
chemical compound, drug(Benzyl benzoate)	Benzyl benzoate	Sigma-Aldrich	CAS 120-51-4; Cat # B6630	
chemical compound, drug(Benzyl alcohol)	Benzyl alcohol	Sigma-Aldrich	CAS 100-51-6; Cat # 305197	

chemical compound, drug(Sucrose)	Sucrose	Sigma-Aldrich	CAS 57-50-1; Cat # S0389	
chemical compound, drug(LIVE/DEAD Fixable Aqua Dead Cell Stain Kit, for 405 nm excitation)	Aqua	ThermoFisher Scientific	Cat # L34957	
chemical compound, drug(Isoflurane, USP)	Isoflurane	Piramal	CAS 26675-46-7	
chemical compound, drug(4',6-Diamidino-2-Phenylindole, Dihydrochloride)	DAPI	ThermoFisher Scientific	CAS 28718-90-3; Cat # 1306	
chemical compound, drug(4',6-Diamidino-2-Phenylindole, Dihydrochloride)	DAPI LIVE/DEAD	Invitrogen	Cat # L34961	
chemical compound, drug(Fluoromount-G)	Fluoromount-G	ThermoFisher Scientific	Cat # 00-4958-02	
antibody(Goat Anti-Mouse IgG - H&L - Fab Fragment Polyclonal Antibody, Unconjugated, Abcam)	F(ab) anti-mouse IgG	Abcam	RRID:AB_955960; Cat # ab6668	
antibody(Anti-Mouse CD45.2 Purified 100 ug antibody, Thermo Fisher Scientific)	Mouse anti-CD45.2	eBioscience	RRID:AB_467261; Cat # 14-0454-82	
antibody(Purified anti-mouse CD16/32 antibody. Low endotoxin, no azide, in PBS)	Rat anti-Mouse CD16/32 (2.4G2)	UCSF Core	UCSF Core Cat# AM004	
commercial assay or kit(DuoSet ELISA Ancillary Reagent Kit 2)	DuoSet ELISA Ancillary Reagent Kit 2	R&D Systems	Cat # DY008	
commercial assay or kit(Mouse CXCL10 DuoSet ELISA)	Mouse CXCl10 DuoSet ELISA	R&D Systems	Cat # DY466	
commercial assay or kit(Pierce™ BCA Protein Assay Kit - Reducing Agent Compatible)	Pierce™ BCA Protein Assay Kit - Reducing Agent Compatible	ThermoFisher Scientific	Cat # 23250	
chemical compound, drug(2-Amino-2-(hydroxymethyl)-1,3-propanediol)	Trizma base, TRIS, TRIS base	Sigma-Aldrich	Cas 77-86-1 ; Cat # T4661	
chemical compound, drug(Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid)	EGTA	Sigma-Aldrich	Cas 67-42-5 ; Cat # E3889	
chemical compound, drug((Ethylenedinitrilo)tetraacetic acid)	EDTA	Sigma-Aldrich	Cas 60-00-4 ; Cat # E9884	
commercial assay or kit(PhosSTOP)	PhosSTOP inhibitor	Roche	Cat # 4906845001	
chemical compound, drug(Sodium deoxycholate, ≥97% (titration))	Sodium deoxycholate	Sigma-Aldrich	Cas 302-95-4; Cat # D6750	

chemical compound, drug(Phenylmethylsulfonyl fluoride)	PMSF	Sigma-Aldrich	Cas 329-98-6; Cat # 10837091001	
chemical compound, drug(1-Fluoro-2,4,-dinitrobenzene)	DNFB	Sigma	Cas 70-34-8; Cat # D1529	
commercial assay or kit(cOmplete protease inhibitor cocktail)	cOmplete protease inhibitor cocktail	Roche	Cat # 11697498001	
other(Advanced RPMI Medium 1640)	RPMI	Gibco	Cat # 12633012	
other(Fetal Bovine Serum)	Fetal Bovine Serum; FBS; FCS	HyClone	Cat # 30396.03	
other(Sodium pyruvate 100 mM)	sodium pyruvate 100 mM	Gibco	Cat # 11360070	
other(HEPES (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid) 1M)	HEPES 1M	Gibco	Cat # 15630080	
other(L-Glutamine 200 mM)	L-Glutamine 200 mM	Gibco	Cat # 25030081	
other(Penicillin-Streptomycin (10,000 U/mL))	Pen-Strep	Gibco	Cat # 15140122	
other(Collagenase VIII)	Collagenase VIII	Sigma-Aldrich	Cat # C2139-500MG	
commercial assay or kit(Invitrogen™ CountBright™ Absolute Counting Beads, for flow cytometry)	Counting Beads	Invitrogen	Cat # C36950	
antibody(CD45 Monoclonal Antibody (30-F11), APC-eFluor 780, eBioscience(TM), Thermo Fisher Scientific)	CD45-APC/eFluor 780 (30-F11)	eBioscience	RRID:AB_1548781; Cat # 47-0451-82	
antibody(CD11b Monoclonal Antibody (M1/70), PE-Cyanine7, eBioscience(TM), Thermo Fisher Scientific)	CD11b-PE/Cy7 (M1/70)	BD Biosciences	RRID:AB_469588; Cat # 25-0112-82	
antibody(PE-Cyanine7 Anti-Human/Mouse CD45R (B220) (RA3-6B2) Antibody, Tonbo Biosciences)	B220-PE/Cy7 (RA3-6B2)	Tonbo Biosciences	RRID:AB_2621849; Cat # 60-0452	
antibody(CD11c Monoclonal Antibody (N418), PE-Cyanine7, eBioscience(TM), Thermo Fisher Scientific)	CD11c-PE/Cy7 (N418)	eBioscience	RRID:AB_469590; Cat # 25-0114-82	
antibody(CD3e Monoclonal Antibody (145-2C11), FITC, eBioscience(TM), Thermo Fisher Scientific)	CD3-FITC (145-2C11)	eBioscience	RRID:AB_464882; Cat # 11-0031-82	
antibody(Brilliant Violet 785™ anti-mouse CD8a antibody, BioLegend)	CD8-BV785 (53-6.7)	Biolegend	RRID:AB_1121880; Cat # 100749	

antibody(Rat Anti-CD4 Monoclonal Antibody, Phycoerythrin Conjugated, Clone GK1.5, BD Biosciences)	CD4-PE (GK1.5)	BD Biosciences	RRID:AB_395014; Cat # 553730	
antibody(Alexa Fluor® 647 anti-mouse TCR γ/δ Antibody)	gdTCR-AF647 (GL3)	Biolegend	RRID:AB_313826; Cat # 118133	
antibody(CD117 (c-Kit) Monoclonal Antibody (2B8), Biotin)	c-Kit-Biotin (ACK2)	eBioscience	RRID:AB_466569; Cat # 13-1171-82	
antibody(FceR1 alpha Monoclonal Antibody (MAR-1)), PE, eBioscience)	FceRI-PE (MAR-1)	eBioscience	RRID:AB_466028; Cat # 12-5898-82	
antibody(CD49b (Integrin alpha 2) Monoclonal Antibody (DX5), PE-Cyanine7, eBioscience)	CD49b-PE/Cy7 (DX5)	eBioscience	RRID:AB_469667; Cat # 25-5971-82	
antibody(Anti-Siglec-F-APC, mouse (clone: REA798))	SiglecF-APC	Miltenyi Biotech	RRID:AB_2653441; Cat # 130-112-333	
antibody(Streptavidin FITC)	SA-FITC	eBioscience	RRID:AB_11431787; Cat # 11-4317-87	
antibody(Ly-6C Monoclonal Antibody (HK1.4), PerCP-Cyanine5.5, eBioscience)	Ly6C-PerCP/Cy5.5 (HK1.4)	eBioscience	RRID:AB_1518762; Cat # 45-5932-82	
antibody(violetFluor™ 450 Anti-Human/Mouse CD11b (M1/70))	CD11b-violet fluor 450 (M1/70)	Tonbo Biosciences	RRID:AB_2621936; Cat # 75-0112	
antibody(AF700 anti-mouse Ly-6G Antibody (1A8))	Ly6G-AF700 (1A8)	BioLegend	RRID:AB_1064045; Cat # 127621	
antibody(CD45.2 Monoclonal Antibody (104), APC-Cy7, eBioscience)	CD45.2-APC/Cy7 (104)	eBioscience	RRID:AB_1272175; Cat # 47-0454-82	
software, algorithm(Igor Pro version 6.3)	IgorPro	WaveMetrics	https://www.wavemetrics.com/order/order_igordownloads6.htm	
software, algorithm(Microsoft Excel 2011)	Microsoft Excel	Microsoft	https://www.microsoft.com/en-us/store/d/excel-2016-for-mac/	
software, algorithm(FIJI)	FIJI	NIH	https://imagej.net/Fiji/Downloads	
software, algorithm(Graphpad Prism 7)	Graphpad Prism	Graphpad	https://www.graphpad.com/scientific-software/prism/	
software, algorithm(R-3.6.0)	R	The R Project for Statistical Computing	https://cran.r-project.org/bin/macosx/	
software, algorithm(Anaconda Python 2.7 version)	Python	Anaconda	https://www.anaconda.com/distribution/	

software, algorithm(HTSeq 0.11.1)	HTSeq	Python Package Index	https://htseq.readthedocs.io/en/release_0.11.1/install.html	
software, algorithm(Trimmomatic)	Trimmomatic	PMID: 24695404	https://github.com/timflutre/trimmomatic	
software, algorithm(Tophat 2.1.1)	Tophat	PMID: 19289445	https://ccb.jhu.edu/software/tophat/	
software, algorithm(EdgeR)	EdgeR	PMID: 19910308; PMID: 22287627	https://bioconductor.org/packages/release/bioc/html/edgeR.html	
software, algorithm(DESeq)	DESeq	PMID: 20979621	https://bioconductor.org/packages/release/bioc/html/DESeq.html	
software, algorithm(FlowJo 10.4.2)	FlowJo	FlowJo	https://www.flowjo.com/solutions/flowjo/downloads	
other(Bovine serum albumin, cold ethanol fraction, pH 5.2, ≥96%)	BSA	Sigma-Aldrich	CAS 9048-46-8; Cat # A4503	
other(Normal Goat Serum)	NGS; Goat serum	Abcam	Cat # ab7481	

Mouse studies

All mice were housed in standard conditions in accordance with standards approved by the Animal Care and Use Committee of the University of California Berkeley (12 hr light-dark cycle, 21˚C). Wild-type C57BL/6 mice were obtained from Charles River or Jackson Laboratories and raised in-house. TSLPR$^{-/-}$ mice were kindly provided by Dr. Steven Ziegler (*Crlf2*^{tm1Jni59})and backcrossed onto C57BL/6. All experiments were performed under the policies and recommendations of the International Association for the Study of Pain and approved by the University of California Berkeley Animal Care and Use Committee. Where appropriate, genotypes were assessed using standard PCR.

MC903 model of atopic dermatitis

MC903 (Calcipotriol; R&D Systems) was applied to the shaved mouse cheek (20 µl of 0.2 mM in ethanol) or rostral back (40 µl of 0.2 mM in ethanol) once per day for 1-12 days using a pipette. 100% ethanol was used. All MC903 studies were performed on 8-12 week old age-matched mice. Behavior, RNA-seq, flow cytometry, and immunohistochemistry were performed on days 1, 2, 3, 5, 8 and/or 12. For AMG 487 experiments in the MC903 model, 50 µL 3.31 mM AMG 487 (Tocris) or 20% HPCD-PBS vehicle was injected subcutaneously one hour prior to recording behavior.[75] Spontaneous scratching was manually scored for the first 30 minutes of observation. Both bout number and length were recorded. Behavioral scoring was performed while blind to experimental condition and mouse genotype.

MC903 RNA isolation and sequencing

On days 1 (six hours post-treatment), 2, 5, or 8 post-treatment, mice treated with MC903 and vehicle were euthanized via isoflurane and cervical dislocation. Cheek skin was removed, flash-frozen in liquid nitrogen, and cryo-homogenized with a mortar and pestle. Ipsilateral trigeminal ganglia were dissected and both skin and trigeminal ganglia were homogenized for three

792 minutes (skin) or one minute (TG) in 1 mL RNAzol RT (Sigma-Aldrich). Thoracic spinal cord was
793 dissected from mice treated with 40 µL MC903 or ethanol on the shaved rostral back skin and
794 homogenized for one minute in 1 mL RNAzol. Large RNA was extracted using RNAzol RT per
795 manufacturer's instructions. RNA pellets were DNase treated (Ambion), resuspended in 50 µL
796 DEPC-treated water, and subjected to poly(A) selection and RNA-seq library preparation (Apollo
797 324) at the Functional Genomics Laboratory (UC Berkeley). Single-end read sequencing (length
798 = 50 bp) was performed by the QB3 Vincent G. Coates Genomic Sequencing Laboratory (UC
799 Berkeley) on an Illumina HiSeq4000. See **Supplementary Table 1** for number of mice per
800 experimental condition and number of mapped reads per sample. Data are available at Gene
801 Expression Omnibus under GSE132173.
802
803 *MC903 RNA sequencing analysis*
804 Reads were mapped to the mm10 mouse genome using Bowtie2 and Tophat, and reads were
805 assigned to transcripts using htseq-count.[113,114] For a given time point, replicate measurements
806 for each gene from treated and control mice were used as input for DESeq (R) and genes with
807 $p_{\text{adjusted}} < 0.05$ (for skin and spinal cord) or $p_{\text{adjusted}} < 0.1$ (for trigeminal ganglia) for at least one
808 time point were retained for analysis.[115,116] For the skin dataset, we collated a set of AD-related
809 immune cell markers, cytokines, atopic dermatitis disease genes, neurite outgrown/axonal
810 guidance genes, and locally expressed neuronal transcripts, and from this list visualized genes
811 that were significantly differentially expressed for at least one time point. For the trigeminal
812 ganglia dataset, we plotted all genes that were significantly differentially expressed for at least
813 one time point. Genes from these lists were plotted with hierarchical clustering using heatmap2
814 (R).
815
816 *Custom gene groups*
817 Genes were clustered into functional groups and significance was evaluated using a
818 permutation test. Briefly, we first tabulated the absolute value of the $\log_2$ fold change of gene
819 expression (between MC903 and EtOH) of each gene in a given group of n genes in turn, and
820 then we calculated the median of these fold change values, z_{true}. We then drew n random genes
821 from the set of all genes detected in the samples and computed the median $\log_2$ fold change as
822 above using this null set, z_{null}. Repeating the latter 10,000 times established a null distribution of
823 median $\log_2$ fold change values; we took the proportion of resampled gene groups that exhibited
824 ($z_{true} \geq z_{null}$) as an empirical p-value reporting the significance of changes in gene expression for
825 a given group of n genes.
826
827 *Flow Cytometry*
828 Skin samples were collected from the cheek of mice at the indicated time points with a 4- or 6-
829 mm biopsy punch into cold RPMI 1640 medium (RPMI; Gibco) and minced into smaller pieces
830 with surgical scissors. When ear skin was collected, whole ears were dissected postmortem into
831 cold RPMI and finely minced with scissors. For isolation of immune cells, skin samples were
832 digested for 1h at 37˚C using 1 U/mL Liberase TM (Roche) and 5 µg/mL DNAse I (Sigma). At
833 the end of the digestion, samples were washed in FACS buffer (PBS with 0.5% FCS and 2 mM
834 EDTA) and filtered through a 70 or 100 µm strainer (Falcon). Cells were stained with
835 LIVE/DEAD fixable stain Aqua in PBS (Invitrogen), then blocked with anti-CD16/32 (UCSF
836 Core) and stained with the following fluorophore-conjugated antibodies (all from eBiosciences
837 unless stated otherwise) in FACS buffer: cKit-Biotin (clone ACK2; secondary stain with SA-
838 FITC), CD11b-violet fluor 450 (Tonbo; clone M1/70), Ly6C-PerCP/Cy5.5 (clone HK1.4), CD49b-
839 PE/Cy7 (clone DX5), CD45.2-APC/Cy7 (clone 104), FceRI-PE (MAR-1), Ly6G-AF700 (clone
840 1A8). 10 µL of counting beads (Invitrogen) were added after the last wash to measure absolute
841 cell counts. For measurement of $CD4^+$ T cells, 6-mm skin biopsy punch samples were digested
842 for 30 minutes at 37˚C using Collagenase VIII (Sigma). At the end of the digestion, cells were

843 washed in RPMI buffer (RPMI with: 5% FCS, 1% penicillin-streptomycin, 2 mM L-glutamine, 10
844 mM HEPES buffer, 1 mM sodium pyruvate). Cells were blocked with anti-CD16/32 (UCSF Core)
845 and stained with the following fluorophore-conjugated antibodies in FACS buffer (PBS with 5%
846 FCS and 2 mM EDTA): CD45-APC-eFluor780 (clone 30-F11; eBiosciences), CD11b-PE/Cy7
847 (clone M1/70; BD Biosciences), B220-PE/Cy7 (clone RA3-6B2; Tonbo Biosciences), CD11c-
848 PE/Cy7 (clone N418; eBiosciences), CD3-FITC (clone 145-2C11; eBiosciences), CD8-BV785
849 (clone 53-6.7; Biolegend), CD4-PE (clone GK1.5; BD Biosciences), gdTCR-AF647 (clone GL3;
850 Biolegend). 10 µL of counting beads (Invitrogen) were added after the last wash to measure
851 absolute cell counts, and samples were resuspended in DAPI LIVE/DEAD (Invitrogen). Blood
852 samples were collected from saphenous vein or from terminal bleed following decapitation. Red
853 blood cells were lysed using ACK lysis buffer (Gibco), and samples were washed with FACS
854 buffer (PBS with 0.5% FCS and 2 mM EDTA), and blocked with anti-CD16/32. Cells were
855 stained with Ly6G-PE (1A8; BD Biosciences), CD11b-violet fluor 450 (M1/70, Tonbo), Ly6C-
856 PerCP/Cy5.5 (HK1.4, Biolegend), and aGr1-APC/Cy7 (RB6-8C5, eBiosciences). For all
857 experiments, single cell suspensions were analyzed on an LSR II or LSR Fortessa (BD
858 Biosciences), and data were analyzed using FlowJo (TreeStar, v.9.9.3) software.
859
860 *Human keratinocyte RNA sequencing*
861 Normal human epidermal keratinocytes from juvenile skin (PromoCell #C-12001) were cultured
862 in PromoCell Keratinocyte Growth Medium 2 and passaged fewer than 5 times. Cells were
863 treated for three hours at room temperature with 100 µM SLIGRL or vehicle (Ringer's + 0.1%
864 DMSO). Total RNA was extracted by column purification (Qiagen RNeasy Mini Kit). RNA was
865 sent to the Vincent J. Coates Sequencing Laboratory at UC Berkeley for standard library
866 preparation and sequenced on an Illumina HiSeq2500 or 4000. Sequences were trimmed
867 (Trimmomatic), mapped (hg19, TopHat) and assigned to transcripts using htseq-count.
868 Differential gene expression was assessed using R (edgeR). Data are available at Gene
869 Expression Omnibus under GSE132174.
870
871 *IHC of whole-mount skin*
872 Staining was performed as previously described.[117,118] Briefly, 8-week old mice were euthanized
873 and the cheek skin was shaved. The removed skin was fixed overnight in 4% PFA, then washed
874 in PBS (3X for 10 min each). Dermal fat was scraped away with a scalpel and skin was washed
875 in PBST (0.3% Triton X-100; 3X for two hours each) then incubated in 1:500 primary antibody
876 (Rabbit anti beta-Tubulin II; Abcam #ab18207 or Rabbit anti-CGRP; Immunostar #24112) in
877 blocking buffer (PBST with 5% goat serum and 20% DMSO) for 6 days at 4°C. Skin was
878 washed as before and incubated in 1:500 secondary antibody (Goat anti-Rabbit Alexa 594;
879 Invitrogen #R37117) in blocking buffer for 3 days at 4°C. Skin was washed in PBST, serially
880 dried in methanol: PBS solutions, incubated overnight in 100% methanol, and finally cleared
881 with a 1:2 solution of benzyl alcohol: benzyl benzoate (BABB; Sigma) before mounting between
882 No. 1.5 coverglass. Whole mount skin samples were imaged on a Zeiss LSM 880 confocal
883 microscope with OPO using a 20x water objective. Image analysis was performed using a
884 custom macro in FIJI. Briefly, maximum intensity z-projections of the beta-tubulin III or CGRP
885 channel were converted to binary files that underwent edge-detection analysis. Regions were
886 defined by circling all stained regions. Region sizes and locations were saved.
887
888 *IHC of sectioned trigeminal ganglia*
889 TG were dissected from 8- to 12-week old adult mice and post-fixed in 4% PFA for one hour.
890 TG were cryo-protected overnight at 4°C in 30% sucrose-PBS, embedded in OCT, and then
891 cryosectioned at 14 µm onto slides for staining. Slides were washed 3x in PBST (0.3% Triton X-
892 100), blocked in 2.5% Normal Goat serum + 2.5% BSA-PBST, washed 3X in PBST, blocked in
893 endogenous IgG block (1:10 F(ab) anti-mouse IgG (Abcam ab6668) + 1:1000 Rat anti-mouse

894 CD16/CD32 (UCSF MAB Core) in 0.3% PBST), washed 3X in PBST and incubated overnight at
895 4°C in 1:1000 primary antibody in PBST + 0.5% Normal Goat Serum + 0.5% BSA. Slides were
896 washed 3x in PBS, incubated 2 hr at RT in 1:1000 secondary antibody, washed 3X in PBS, and
897 then incubated 30 min in 1:2000 DAPI-PBS. Slides were washed 3x in PBS and mounted in
898 Fluoromount-G with No. 1.5 coverglass. Primary antibodies used: Mouse anti-CD45
899 (eBioscience #14-054-82) and Chicken anti-Peripherin (Abcam #39374). Secondary antibodies
900 used: Goat anti-Chicken Alexa 594 (ThermoFisher #A11042) and Goat anti-Mouse Alexa 488
901 (Abcam #150117). DAPI (ThermoFisher #D1306) was also used to mark nuclei. Imaging of TG
902 IHC experiments was performed on an Olympus IX71 microscope with a Lambda LS-xl light
903 source (Sutter Instruments). For TG IHC analysis, images were analyzed using automated
904 scripts in FIJI (ImageJ) software. Briefly, images were separated into the DAPI, CD45, and
905 Peripherin channels. The minimum/maximum intensity thresholds were batch-adjusted to pre-
906 determined levels, and adjusted images were converted to binary files. Regions were defined by
907 circling all stained regions with pre-determined size-criteria. Region sizes and locations were
908 saved. All scripts are available upon request.
909
910 *Neutrophil depletion*
911 Neutrophils were acutely depleted using intraperitoneal injection with 250 µg aGR1 in PBS
912 (clone RB6-8C5, a gift from D. Portnoy, UC Berkeley, or from Biolegend), 16-24 hours before
913 behavioral and flow cytometry experiments. Depletion was verified using flow cytometry on
914 blood collected from terminal bleed following decapitation. For longer depletion experiments
915 using the MC903 model, mice were injected (with 250 µg aGR1 in PBS or PBS vehicle, i.p.)
916 beginning one day prior to MC903 administration and each afternoon thereafter through day 7 of
917 the model, or on days 8-11 for measurement of day 12 itch behaviors, and blood was collected
918 via saphenous venipuncture at days 3, 5, or by decapitation at day 8 to verify depletion.
919
920 *CXCL10 ELISA measurements in skin*
921 Neutrophil-depleted or uninjected mice were treated with MC903 or ethanol for 7 days. On day
922 8, 6-mm biopsy punches of cheek skin were harvested, flash-frozen in liquid nitrogen, cryo-
923 homogenized by mortar and pestle, and homogenized on ice for three minutes at maximum
924 speed in 0.5 mL of the following tissue homogenization buffer (all reagents from Sigma unless
925 stated otherwise): 100 mM Tris, pH 7.4; 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-
926 100, and 0.5% Sodium deoxycholate in ddH2O; on the day of the experiment, 200 mM fresh
927 PMSF in 100% ethanol was added to 1mM, with 1 tablet cOmplete protease inhibitor (Roche)
928 per 50 mL, and 5 tablets PhosSTOP inhibitor (Roche) per 50 mL buffer. Tissues were agitated
929 in buffer for two hours at 4°C, and centrifuged at 13,000 rpm for 20 minutes at 4°C.
930 Supernatants were aliquoted and stored at -80°C for up to one week. After thawing, samples
931 were centrifuged at 10,000 rpm for five minutes at 4°C. Protein content of skin homogenates
932 was quantified by BCA (Thermo Scientific) and homogenates were diluted to 2 mg/mL protein in
933 PBS and were subsequently diluted 1:2 in Reagent Diluent (R&D Systems). CXCL10 protein
934 was quantified using the Mouse CXCL10 Duoset ELISA kit (R&D Systems; #DY466-05)
935 according to manufacturer's instructions. Plate was read at 450 nm and CXCL10 was quantified
936 using a seven-point standard curve (with blank and buffer controls) and fitted with a 4-parameter
937 logistic curve.
938
939 *Acute itch behavior*
940 Itch behavioral measurements were performed as previously described.[56,119,120] Mice were
941 shaved one week prior to itch behavior and acclimated in behavior chambers once for thirty
942 minutes at the same time of day on the day prior to the experiment. Behavioral experiments
943 were performed during the day. Compounds injected: 1 µg carrier-free CXCL1 (R&D systems) in
944 PBS, 3.31 mM AMG 487 (Tocris, prepared from 100 mM DMSO stock) in 20% HPCD-PBS, 50

945 mM Chloroquine diphosphate (Sigma) in PBS, along with corresponding vehicle controls. Acute
946 pruritogens were injected using the cheek model (20 µL, subcutaneous/s.c.) of itch, as
947 previously described.[56] AMG 487 (50 µL) or vehicle was injected s.c. into the rostral back skin
948 one hour prior to recording of behavior. Behavioral scoring was performed as described above.
949
950 *Lipidomics*
951 Skin was collected from the cheek of mice post-mortem with a 6-mm biopsy punch and
952 immediately flash-frozen in liquid nitrogen. Lipid mediators and metabolites were quantified via
953 liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described before.[121] In brief,
954 skin was homogenized in cold methanol to stabilize lipid mediators. Deuterated internal
955 standards (PGE_2-d4, LTB_4-d4, 15-HETE-d8, LXA_4-d5, DHA-d5, AA-d8) were added to samples
956 to calculate extraction recovery. LC-MS/MS system consisted of an Agilent 1200 Series HPLC,
957 Luna C18 column (Phenomenex, Torrance, CA, USA), and AB Sciex QTRAP 4500 mass
958 spectrometer. Analysis was carried out in negative ion mode, and lipid 30 mediators quantified
959 using scheduled multiple reaction monitoring (MRM) mode using four to six specific transition
960 ions per analyte.[122]
961
962 *1-Fluoro-2,4-dinitrobenzene (DNFB) model of atopic dermatitis*
963 The DNFB model was conducted as described previously.[63] Briefly, the rostral backs of
964 isofluorane-anesthetized mice were shaved using surgical clippers. Two days after shaving,
965 mice were treated with 25 µL 0.5% DNFB (Sigma) dissolved in 4:1 acetone:olive oil vehicle on
966 the rostral back using a pipette. Five days after the initial DNFB sensitization, mice were
967 challenged with 40 µL 0.2% DNFB or 4:1 acetone:olive oil vehicle applied to the outer surface of
968 the right ear. Twenty-four hours after DNFB or vehicle challenge, mice were euthanized and ear
969 skin was harvested for flow cytometry.
970
971 *Statistical analyses*
972 Different control experimental conditions (*e.g.* uninjected versus PBS-injected animals) were
973 pooled when the appropriate statistical test showed they were not significantly different
974 (Supplementary Table 2). For all experiments except RNA-seq (see above), the following
975 statistical tests were used, where appropriate: Student's t-test, one-way ANOVA with Tukey-
976 Kramer post hoc comparison, and two-way ANOVA with Tukey Kramer or Sidak's post-hoc
977 comparison. Bar graphs show mean ± SEM. Statistical analyses were performed using PRISM
978 7 software (GraphPad). For all p values, *=0.01<p<0.05, **=0.001<p<0.01,
979 ***=0.0001<p<0.001, and ****=p<0.0001.
980
981 **Acknowledgements**
982 The authors would like to thank members of the Bautista and Barton labs for helpful discussions
983 on the data. We are grateful to S. Ziegler (Ben Aroya Research Institute) for the gift of the
984 $TSLPR^{-/-}$ mouse. We also thank M. Pellegrino and L. Thé for pilot studies on human
985 keratinocyte transcriptome, and T. Morita and J. Wong for technical assistance with mouse
986 behavioral experiments. D.M.B. is supported by the NIH (AR059385; NS07224 and NS098097,
987 also to R.B.B) and the Howard Hughes Medical Institute. G.M.B. is supported by the NIH
988 (AI072429, AI063302, AI104914, AI105184) and the Burroughs Wellcome Fund. J.D. was
989 supported by a Long-Term Fellowship from the Human Frontier Science Program (LT-
990 000081/2013-L). K.G. is supported by NIH grant EY026082. Confocal imaging experiments
991 were conducted at the CRL Molecular Imaging Center, supported by the Helen Wills
992 Neuroscience Institute (UC Berkeley). We would like to thank H. Aaron and F. Ives for their
993 microscopy training and assistance. This work used the Functional Genomics Laboratory and
994 the Vincent J. Coates Genomics Sequencing Laboratory at UC Berkeley, supported by NIH S10
995 OD018174 Instrumentation Grant.

996
997 **Conflict of interest statement**
998 The authors declare no conflict of interest.
999
1000 **References**

1001 1. Matterne, U., Apfelbacher, C., Loerbroks, A., Schwarzer, T., Büttner, M., Ofenloch, R.,
1002 Diepgen, T. & Weisshaar, E. Prevalence, correlates and characteristics of chronic
1003 pruritus: a population-based cross-sectional study. *Acta Derm. Venereol.* **91,** 674–679
1004 (2011).
1005 2. Mollanazar, N. K., Smith, P. K. & Yosipovitch, G. Mediators of Chronic Pruritus in Atopic
1006 Dermatitis: Getting the Itch Out? *Clin Rev Allergy Immunol* **51,** 263–292 (2016).
1007 3. Dalgard, F. J., Gieler, U., Tomas-Aragones, L., Lien, L., Poot, F., Jemec, G. B. E., Misery,
1008 L., Szabo, C., Linder, D., Sampogna, F., Evers, A. W. M., Halvorsen, J. A., Balieva, F.,
1009 Szepietowski, J., Romanov, D., Marron, S. E., Altunay, I. K., Finlay, A. Y., Salek, S. S. &
1010 Kupfer, J. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter
1011 Study among Dermatological Out-Patients in 13 European Countries. *J. Invest. Dermatol.*
1012 **135,** 984–991 (2015).
1013 4. Ständer, S. & Steinhoff, M. Pathophysiology of pruritus in atopic dermatitis: an overview.
1014 *Exp. Dermatol.* **11,** 12–24 (2002).
1015 5. Oaklander, A. L. Neuropathic itch. *Semin. Cutan. Med. Surg.* **30,** 87–92 (2011).
1016 6. Dhand, A. & Aminoff, M. J. The neurology of itch. *Brain* **137,** 313–322 (2014).
1017 7. Yosipovitch, G. & Papoiu, A. D. P. What causes itch in atopic dermatitis? *Curr. Allergy*
1018 *Asthma Rep.* **8,** 306–311 (2008).
1019 8. Ikoma, A., Steinhoff, M., Ständer, S., Yosipovitch, G. & Schmelz, M. The neurobiology of
1020 itch. *Nat. Rev. Neurosci.* **7,** 535–547 (2006).
1021 9. Spergel, J. M. & Paller, A. S. Atopic dermatitis and the atopic march. *J Allergy Clin*
1022 *Immunol* **112,** S118-27 (2003).
1023 10. Zheng, T., Yu, J., Oh, M. H. & Zhu, Z. The atopic march: Progression from atopic
1024 dermatitis to allergic rhinitis and asthma. *Allergy, Asthma Immunol. Res.* **3,** 67–73 (2011).
1025 11. Ewald, D. A., Noda, S., Oliva, M., Litman, T., Nakajima, S., Li, X., Xu, H., Workman, C.
1026 T., Scheipers, P., Svitacheva, N., Labuda, T., Krueger, J. G., Suárez-Fariñas, M.,
1027 Kabashima, K. & Guttman-Yassky, E. Major differences between human atopic dermatitis
1028 and murine models, as determined by using global transcriptomic profiling. *J. Allergy Clin.*
1029 *Immunol.* **139,** 562–571 (2017).
1030 12. Choy, D. F., Hsu, D. K., Seshasayee, D., Fung, M. A., Modrusan, Z., Martin, F., Liu, F.-T.
1031 & Arron, J. R. Comparative transcriptomic analyses of atopic dermatitis and psoriasis
1032 reveal shared neutrophilic inflammation. *J. Allergy Clin. Immunol.* **130,** 1335–43.e5
1033 (2012).
1034 13. Guttman-Yassky, E., Suárez-Fariñas, M., Chiricozzi, A., Nograles, K. E., Shemer, A.,
1035 Fuentes-Duculan, J., Cardinale, I., Lin, P., Bergman, R., Bowcock, A. M. & Krueger, J. G.
1036 Broad defects in epidermal cornification in atopic dermatitis identified through genomic
1037 analysis. *J. Allergy Clin. Immunol.* **124,** (2009).
1038 14. Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., De Guzman Strong,
1039 C., Krueger, J. G. & Guttman-Yassky, E. Intrinsic atopic dermatitis shows similar TH2 and
1040 higher T H17 immune activation compared with extrinsic atopic dermatitis. *J. Allergy Clin.*
1041 *Immunol.* **132,** 361–370 (2013).
1042 15. Jabbari, A., Suárez-Fariñas, M., Dewell, S. & Krueger, J. G. Transcriptional profiling of
1043 psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. *J.*
1044 *Invest. Dermatol.* **132,** 246–9 (2012).
1045 16. Nattkemper, L. A., Tey, H. L., Valdes-Rodriguez, R., Lee, H., Mollanazar, N. K., Albornoz,
1046 C., Sanders, K. M. & Yosipovitch, G. The Genetics of Chronic Itch: Gene Expression in

1047 the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. *J. Invest.*
1048 *Dermatol.* **138,** 1311–1317 (2018).
1049 17. Dai, J., Choo, M. K., Park, J. M. & Fisher, D. E. Topical ROR Inverse Agonists Suppress
1050 Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis. *J.*
1051 *Invest. Dermatol.* **137,** 2523–2531 (2017).
1052 18. Li, M., Hener, P., Zhang, Z., Ganti, K. P., Metzger, D. & Chambon, P. Induction of thymic
1053 stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic
1054 dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. *J.*
1055 *Invest. Dermatol.* **129,** 498–502 (2009).
1056 19. Li, M., Hener, P., Zhang, Z., Kato, S., Metzger, D. & Chambon, P. Topical vitamin D3 and
1057 low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and
1058 trigger an atopic dermatitis. *Proc. Natl. Acad. Sci.* **103,** 11736–11741 (2006).
1059 20. Zhang, Z., Hener, P., Frossard, N., Kato, S., Metzger, D., Li, M. & Chambon, P. Thymic
1060 stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates
1061 experimental asthma. *Proc. Natl. Acad. Sci.* **106,** 1536–1541 (2009).
1062 21. Moosbrugger-Martinz, V., Schmuth, M. & Dubrac, S. A Mouse Model for Atopic Dermatitis
1063 Using Topical Application of Vitamin D3 or of Its Analog MC903. *Methods Mol. Biol.* **1559,**
1064 91–106 (2017).
1065 22. Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A.
1066 M., Xu, A. Z., Tripathi, S. V., Luo, J., Gao, X., Yang, L., Hamilton, S. L., Wang, P. L.,
1067 Brestoff, J. R., Council, M. L., Brasington, R., Schaffer, A., Brombacher, F., Hsieh, C.-S.,
1068 Gereau, R. W., Miller, M. J., Chen, Z.-F., Hu, H., Davidson, S., Liu, Q. & Kim, B. S.
1069 Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch.
1070 *Cell* **171,** 217-228.e13 (2017).
1071 23. Morita, T., McClain, S. P., Batia, L. M., Pellegrino, M., Wilson, S. R., Kienzler, M. A.,
1072 Lyman, K., Olsen, A. S. B., Wong, J. F., Stucky, C. L., Brem, R. B. & Bautista, D. M.
1073 HTR7 Mediates Serotonergic Acute and Chronic Itch. *Neuron* 1–15 (2015).
1074 doi:10.1016/j.neuron.2015.05.044
1075 24. Kim, D., Kobayashi, T. & Nagao, K. Research Techniques Made Simple: Mouse Models
1076 of Atopic Dermatitis. *J. Invest. Dermatol.* **139,** 984-990.e1 (2019).
1077 25. Cevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G.,
1078 Buhl, T., Ikoma, A., Buddenkotte, J., Soumelis, V., Feld, M., Alenius, H., Dillon, S. R.,
1079 Carstens, E. E., Homey, B., Basbaum, A. I. & Steinhoff, M. A sensory neuron-expressed
1080 IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1.
1081 *J. Allergy Clin. Immunol.* **133,** 448–460 (2014).
1082 26. Meng, J., Moriyama, M., Feld, M., Buddenkotte, J., Buhl, T., Szöllösi, A., Zhang, J., Miller,
1083 P., Ghetti, A., Fischer, M., Reeh, P. W., Shan, C., Wang, J. & Steinhoff, M. New
1084 mechanism underlying IL-31-induced atopic dermatitis. *J. Allergy Clin. Immunol.* (2017).
1085 doi:10.1016/j.jaci.2017.12.1002
1086 27. Martel, B. C., Lovato, P., Bäumer, W. & Olivry, T. Translational animal models of atopic
1087 dermatitis for preclinical studies. *Yale J. Biol. Med.* **90,** 389–402 (2017).
1088 28. Rattenholl, A. & Steinhoff, M. Role of proteinase-activated receptors in cutaneous biology
1089 and disease. *Drug Dev. Res.* **59,** 408–416 (2003).
1090 29. Yosipovitch, G. Dry skin and impairment of barrier function associated with itch - new
1091 insights. *Int J Cosmet Sci* **26,** 1–7 (2004).
1092 30. Briot, A., Lacroix, M., Robin, A., Steinhoff, M., Deraison, C. & Hovnanian, A. Par2
1093 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in
1094 netherton syndrome adult mouse model. *J. Invest. Dermatol.* **130,** 2736–2742 (2010).
1095 31. Demehri, S., Morimoto, M., Holtzman, M. J. & Kopan, R. Skin-derived TSLP triggers
1096 progression from epidermal-barrier defects to asthma. *PLoS Biol.* **7,** e1000067 (2009).
1097 32. Gao, P. S., Rafaels, N. M., Mu, D., Hand, T., Murray, T., Boguniewicz, M., Hata, T.,

1098 Schneider, L., Hanifin, J. M., Gallo, R. L., Gao, L., Beaty, T. H., Beck, L. A., Leung, D. Y.
1099 M. & Barnes, K. C. Genetic variants in thymic stromal lymphopoietin are associated with
1100 atopic dermatitis and eczema herpeticum. *J. Allergy Clin. Immunol.* **125,** 1403–1407
1101 (2010).
1102 33. Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F.,
1103 Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R. & Artis, D. TSLP elicits IL-33-
1104 independent innate lymphoid cell responses to promote skin inflammation. *Sci Transl*
1105 *Med* **5,** 170ra16-170ra16 (2013).
1106 34. Hidaka, T., Ogawa, E., Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T.,
1107 Fujimura, T., Aiba, S., Nakayama, K., Okuyama, R. & Yamamoto, M. The aryl
1108 hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the
1109 neurotrophic factor artemin. *Nat. Immunol.* **18,** 64–73 (2017).
1110 35. Kou, K., Nakamura, F., Aihara, M., Chen, H., Seto, K., Komuri-Yamaguchi, J., Kambara,
1111 T., Nagashima, Y., Goshima, Y. & Ikezawa, Z. Decreased expression of semaphorin-3A,
1112 a neurite-collapsing factor, is associated with itch in psoriatic skin. *Acta Derm. Venereol.*
1113 **92,** 521–528 (2012).
1114 36. Tominaga, M. & Takamori, K. Recent Advances in the Study of Itching An Update on
1115 Peripheral Mechanisms and Treatments of Itch. **36,** 1241–1247 (2013).
1116 37. Tominaga, M., Ozawa, S., Ogawa, H. & Takamori, K. A hypothetical mechanism of
1117 intraepidermal neurite formation in NC/Nga mice with atopic dermatitis. *J. Dermatol. Sci.*
1118 **46,** 199–210 (2007).
1119 38. Tominaga, M. & Takamori, K. Itch and nerve fibers with special reference to atopic
1120 dermatitis: therapeutic implications. *J. Dermatol.* **41,** 205–212 (2014).
1121 39. Haas, S., Capellino, S., Phan, N. Q., Böhm, M., Luger, T. A., Straub, R. H. & Ständer, S.
1122 Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in
1123 lesional skin of chronic pruritus and prurigo nodularis. *J. Dermatol. Sci.* **58,** 193–197
1124 (2010).
1125 40. Kamo, A., Tominaga, M., Taneda, K., Ogawa, H. & Takamori, K. Neurotropin inhibits the
1126 increase in intraepidermal nerve density in the acetone-treated dry-skin mouse model.
1127 *Clin. Exp. Dermatol.* **38,** 665–668 (2013).
1128 41. Oaklander, A. L. & Siegel, S. M. Cutaneous innervation: Form and function. *J. Am. Acad.*
1129 *Dermatol.* **53,** 1027–1037 (2005).
1130 42. Schüttenhelm, B. N., Duraku, L. S., Dijkstra, J. F., Walbeehm, E. T. & Holstege, J. C.
1131 Differential Changes in the Peptidergic and the Non-Peptidergic Skin Innervation in Rat
1132 Models for Inflammation, Dry Skin Itch, and Dermatitis. *J. Invest. Dermatol.* **135,** 2049–
1133 2057 (2015).
1134 43. Pereira, M. P., Mühl, S., Pogatzki-Zahn, E. M., Agelopoulos, K. & Ständer, S.
1135 Intraepidermal Nerve Fiber Density: Diagnostic and Therapeutic Relevance in the
1136 Management of Chronic Pruritus: a Review. *Dermatol. Ther. (Heidelb).* **6,** 509–517
1137 (2016).
1138 44. Tominaga, M., Tengara, S., Kamo, A., Ogawa, H. & Takamori, K. Psoralen-ultraviolet A
1139 therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation
1140 in atopic dermatitis. *J. Dermatol. Sci.* **55,** 40–46 (2009).
1141 45. Palmer, C. N. a, Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P.,
1142 Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., O'Regan, G. M., Watson,
1143 R. M., Cecil, J. E., Bale, S. J., Compton, J. G., DiGiovanna, J. J., Fleckman, P., Lewis-
1144 Jones, S., Arseculeratne, G., Sergeant, A., Munro, C. S., El Houate, B., McElreavey, K.,
1145 Halkjaer, L. B., Bisgaard, H., Mukhopadhyay, S. & McLean, W. H. I. Common loss-of-
1146 function variants of the epidermal barrier protein filaggrin are a major predisposing factor
1147 for atopic dermatitis. *Nat. Genet.* **38,** 441–446 (2006).
1148 46. Sandilands, A., Terron-Kwiatkowski, A., Hull, P. R., O'Regan, G. M., Clayton, T. H.,

1149 Watson, R. M., Carrick, T., Evans, A. T., Liao, H., Zhao, Y., Campbell, L. E., Schmuth,
1150 M., Gruber, R., Janecke, A. R., Elias, P. M., van Steensel, M. A. M., Nagtzaam, I., van
1151 Geel, M., Steijlen, P. M., Munro, C. S., Bradley, D. G., Palmer, C. N. A., Smith, F. J. D.,
1152 McLean, W. H. I. & Irvine, A. D. Comprehensive analysis of the gene encoding filaggrin
1153 uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat.*
1154 *Genet.* **39,** 650–654 (2007).
1155 47. Gittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J.,
1156 Wang, C. Q. F., Mitsui, H., Cardinale, I., De Guzman Strong, C., Krueger, J. G. &
1157 Guttman-Yassky, E. Progressive activation of TH2/TH22 cytokines and selective
1158 epidermal proteins characterizes acute and chronic atopic dermatitis. *J. Allergy Clin.*
1159 *Immunol.* **130,** 1344–1354 (2012).
1160 48. Oetjen, L. K. & Kim, B. S. Interactions of the immune and sensory nervous systems in
1161 atopy. *FEBS J.* **285,** 3138–3151 (2018).
1162 49. Mansouri, Y. & Guttman-Yassky, E. Immune Pathways in Atopic Dermatitis, and
1163 Definition of Biomarkers through Broad and Targeted Therapeutics. *J Clin Med* **4,** 858–
1164 873 (2015).
1165 50. Guttman-Yassky, E. & Krueger, J. G. Atopic dermatitis and psoriasis: two different
1166 immune diseases or one spectrum? *Curr. Opin. Immunol.* **48,** 68–73 (2017).
1167 51. Dong, X. X. & Dong, X. X. Peripheral and Central Mechanisms of Itch. *Neuron* **98,** 482–
1168 494 (2018).
1169 52. Hashimoto, T., Rosen, J. D., Sanders, K. M. & Yosipovitch, G. Possible role of
1170 neutrophils in itch. *Itch* 1 (2018). doi:10.1097/itx.0000000000000017
1171 53. Fogh, K., Herlin, T. & Kragballe, K. Eicosanoids in skin of patients with atopic dermatitis:
1172 prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. *J.*
1173 *Allergy Clin. Immunol.* **83,** 450–455 (1989).
1174 54. Ghasemlou, N., Chiu, I. M., Julien, J.-P. & Woolf, C. J. CD11b $^{+}$Ly6G $^{-}$myeloid cells
1175 mediate mechanical inflammatory pain hypersensitivity. *Proc. Natl. Acad. Sci.* 201501372
1176 (2015). doi:10.1073/pnas.1501372112
1177 55. Sivick, K. E., Arpaia, N., Reiner, G. L., Lee, B. L., Russell, B. R. & Barton, G. M. Toll-like
1178 receptor-deficient mice reveal how innate immune signaling influences Salmonella
1179 virulence strategies. *Cell Host Microbe* **15,** 203–213 (2014).
1180 56. Shimada, S. G. & LaMotte, R. H. Behavioral differentiation between itch and pain in
1181 mouse. *Pain* **139,** 681–687 (2008).
1182 57. Deftu, A. F., Filippi, A., Shibasaki, K., Gheorghe, R. O., Chiritoiu, M. & Ristoiu, V.
1183 Chemokine (C-X-C motif) ligand 1 (CXCL1) and chemokine (C-X-C motif) ligand 2
1184 (CXCL2) modulate the activity of TRPV1+/IB4+ cultured rat dorsal root ganglia neurons
1185 upon short-term and acute application. *J. Physiol. Pharmacol.* **68,** 385–395 (2017).
1186 58. Deftu, A. F., Filippi, A., Gheorghe, R. O. & Ristoiu, V. CXCL1 activates TRPV1 via Gi/o
1187 protein and actin filaments. *Life Sci.* **193,** 282–291 (2018).
1188 59. Carpino, N., Thierfelder, W. E., Chang, M., Saris, C., Turner, S. J., Ziegler, S. F. & Ihle, J.
1189 N. Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell
1190 development. *Mol. Cell. Biol.* **24,** 2584–2592 (2004).
1191 60. Briot, A., Deraison, C., Lacroix, M., Bonnart, C., Robin, A., Besson, C., Dubus, P. &
1192 Hovnanian, A. Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated
1193 thymic stromal lymphopoietin expression in Netherton syndrome. *J. Exp. Med.* **206,**
1194 1135–1147 (2009).
1195 61. Zhang, Y., Yan, J., Hu, R., Sun, Y., Ma, Y., Chen, Z. & Jiang, H. Microglia are involved in
1196 pruritus induced by DNFB via the CX3CR1/p38 MAPK pathway. *Cell. Physiol. Biochem.*
1197 **35,** 1023–1033 (2015).
1198 62. Kitamura, A., Takata, R., Aizawa, S., Watanabe, H. & Wada, T. A murine model of atopic
1199 dermatitis can be generated by painting the dorsal skin with hapten twice 14 days apart.

1200 *Sci. Rep.* **8,** 1–9 (2018).
1201 63. Solinski, H. J., Dranchak, P., Oliphant, E., Gu, X., Earnest, T. W., Braisted, J., Inglese, J.
1202 & Hoon, M. A. Inhibition of natriuretic peptide receptor 1 reduces itch in mice. *Sci. Transl.*
1203 *Med.* **11,** eaav5464 (2019).
1204 64. Usoskin, D., Furlan, A., Islam, S., Abdo, H., Lönnerberg, P., Lou, D., Hjerling-Leffler, J.,
1205 Haeggström, J., Kharchenko, O., Kharchenko, P. V, Linnarsson, S. & Ernfors, P.
1206 Unbiased classification of sensory neuron types by large-scale single-cell RNA
1207 sequencing. *Nat. Neurosci.* **18,** 145–153 (2015).
1208 65. Takeda, M., Takahashi, M. & Matsumoto, S. Contribution of the activation of satellite glia
1209 in sensory ganglia to pathological pain. *Neurosci. Biobehav. Rev.* **33,** 784–792 (2009).
1210 66. Huang, J., Polgár, E., Solinski, H. J., Mishra, S. K., Tseng, P.-Y., Iwagaki, N., Boyle, K.
1211 A., Dickie, A. C., Kriegbaum, M. C., Wildner, H., Zeilhofer, H. U., Watanabe, M., Riddell,
1212 J. S., Todd, A. J. & Hoon, M. A. Circuit dissection of the role of somatostatin in itch and
1213 pain. *Nat. Neurosci. 2018* 1 (2018). doi:10.1038/s41593-018-0119-z
1214 67. Solinski, H. J., Kriegbaum, M. C., Tseng, P. Y., Earnest, T. W., Gu, X., Barik, A., Chesler,
1215 A. T. & Hoon, M. A. Nppb Neurons Are Sensors of Mast Cell-Induced Itch. *Cell Rep.* **26,**
1216 3561-3573.e4 (2019).
1217 68. Shiratori-Hayashi, M., Koga, K., Tozaki-Saitoh, H., Kohro, Y., Toyonaga, H., Yamaguchi,
1218 C., Hasegawa, A., Nakahara, T., Hachisuka, J., Akira, S., Okano, H., Furue, M., Inoue, K.
1219 & Tsuda, M. STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies
1220 chronic itch. *Nat. Med.* **21,** 1–8 (2015).
1221 69. Ioannidis, L. J., Nie, C. Q., Ly, A., Ryg-Cornejo, V., Chiu, C. Y. & Hansen, D. S.
1222 Monocyte- and Neutrophil-Derived CXCL10 Impairs Efficient Control of Blood-Stage
1223 Malaria Infection and Promotes Severe Disease. *J. Immunol.* **196,** 1227–1238 (2016).
1224 70. Kanda, N., Shimizu, T., Tada, Y. & Watanabe, S. IL-18 enhances IFN-γ-induced
1225 production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. *Eur. J. Immunol.*
1226 **37,** 338–350 (2007).
1227 71. Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M. & Tokura, Y. Possible pathogenic
1228 role of Th17 cells for atopic dermatitis. *J. Invest. Dermatol.* **128,** 2625–2630 (2008).
1229 72. Michalec, L., Choudhury, B. K., Postlethwait, E., Wild, J. S., Alam, R., Lett-Brown, M. &
1230 Sur, S. CCL7 and CXCL10 Orchestrate Oxidative Stress-Induced Neutrophilic Lung
1231 Inflammation. *J. Immunol.* **168,** 846–852 (2002).
1232 73. Padovan, E., Spagnoli, G. C., Ferrantini, M. & Heberer, M. IFN-a2a induces IP-
1233 10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and
1234 enhances their capacity to attract and stimulate CD8+ effector T cells. *J. Leukoc. Biol.* **71,**
1235 669–676 (2002).
1236 74. Tamassia, N., Calzetti, F., Ear, T., Cloutier, A., Gasperini, S., Bazzoni, F., McDonald, P.
1237 P. & Cassatella, M. A. Molecular mechanisms underlying the synergistic induction of
1238 CXCL10 by LPS and IFN-?? in human neutrophils. *Eur. J. Immunol.* **37,** 2627–2634
1239 (2007).
1240 75. Qu, L., Fu, K., Yang, J., Shimada, S. G. & LaMotte, R. H. *CXCR3 chemokine receptor*
1241 *signaling mediates itch in experimental allergic contact dermatitis*. *Pain* **156,** (2015).
1242 76. Koro, O., Furutani, K., Hide, M., Yamada, S. & Yamamoto, S. Chemical mediators in
1243 atopic dermatitis: Involvement of leukotriene B4 released by a type I allergic reaction in
1244 the pathogenesis of atopic dermatitis. *J. Allergy Clin. Immunol.* **103,** 663–670 (1999).
1245 77. Mihm, M. C., Soter, N. A., Dvorak, H. F. & Austen, K. F. The structure of normal skin and
1246 the morphology of atopic eczema. *J. Invest. Dermatol.* **67,** 305–312 (1976).
1247 78. Shalit, M., Campbell, D. E., von Allmen, C., Atkins, P. C., Douglas, S. D. & Zweiman, B.
1248 Neutrophil activation in human inflammatory skin reactions. *J. Allergy Clin. Immunol.* **80,**
1249 87–93 (1987).
1250 79. Sumida, H., Yanagida, K., Kita, Y., Abe, J., Matsushima, K., Nakamura, M., Ishii, S.,

1251 Sato, S. & Shimizu, T. Interplay between CXCR2 and BLT1 facilitates neutrophil
1252 infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced
1253 psoriasis. *J. Immunol.* **192,** 4361–4369 (2014).
1254 80. Perkins, N. M. & Tracey, D. J. Hyperalgesia due to nerve injury: role of neutrophils.
1255 *Neuroscience* **101,** 745–757 (2000).
1256 81. Guerrero, A. T. G., Verri, W. A., Cunha, T. M., Silva, T. A., Schivo, I. R. S., Dal-Secco, D.,
1257 Canetti, C., Rocha, F. A. C., Parada, C. A., Cunha, F. Q. & Ferreira, S. H. Involvement of
1258 LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and
1259 PGE2. *J. Leukoc. Biol.* **83,** 122–130 (2008).
1260 82. Cunha, J. M., Sachs, D., Canetti, C. A., Poole, S., Ferreira, S. H. & Cunha, F. Q. The
1261 critical role of leukotriene B 4 in antigen-induced mechanical hyperalgesia in immunised
1262 rats. *Br. J. Pharmacol.* **139,** 1135–1145 (2003).
1263 83. Finley, a, Chen, Z., Esposito, E., Cuzzocrea, S., Sabbadini, R. & Salvemini, D.
1264 Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism.
1265 *PLoS One* **8,** e55255 (2013).
1266 84. Carreira, E. U., Carregaro, V., Teixeira, M. M., Moriconi, A., Aramini, A., Verri, W. A.,
1267 Ferreira, S. H., Cunha, F. Q. & Cunha, T. M. Neutrophils recruited by CXCR1/2 signalling
1268 mediate post-incisional pain. *Eur J Pain* **17,** 654–663 (2013).
1269 85. Levine, J. D., Khasar, S. G. & Green, P. G. Neurogenic inflammation and arthritis. *Ann.*
1270 *N. Y. Acad. Sci.* **1069,** 155–167 (2006).
1271 86. Schön, M., Kubitza, R. C., Ruzicka, T., Schön, M. P. & Denzer, D. Critical Role of
1272 Neutrophils for the Generation of Psoriasiform Skin Lesions in Flaky Skin Mice. *J. Invest.*
1273 *Dermatol.* **114,** 976–983 (2003).
1274 87. Oyoshi, M. K., He, R., Li, Y., Mondal, S., Yoon, J., Afshar, R., Chen, M., Lee, D. M., Luo,
1275 H. R., Luster, A. D., Cho, J. S., Miller, L. S., Larson, A., Murphy, G. F. & Geha, R. S.
1276 Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin
1277 inflammation. *Immunity* **37,** 747–758 (2012).
1278 88. Meixiong, J., Anderson, M., Limjunyawong, N., Sabbagh, M. F., Hu, E., Mack, M. R.,
1279 Oetjen, L. K., Wang, F., Kim, B. S. & Dong, X. Activation of Mast-Cell-Expressed Mas-
1280 Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. *Immunity* **50,** 1163-
1281 1171.e5 (2019).
1282 89. Chatterjea, D. & Martinov, T. Mast cells: versatile gatekeepers of pain. *Mol. Immunol.* **63,**
1283 38–44 (2015).
1284 90. Pinho-Ribeiro, F. A., Haarsma, R., Yang, N. J., Blake, K. J., Portley, M., Chiu, I. M.,
1285 Baddal, B., O'Seaghdha, M., Wessels, M. R., Verri, W. A. & Dale, J. B. Blocking Neuronal
1286 Signaling to Immune Cells Treats Streptococcal Invasive Infection. *Cell* **173,** 1083-
1287 1097.e22 (2018).
1288 91. Salvemini, D., Little, J. W., Doyle, T. & Neumann, W. L. Roles of reactive oxygen and
1289 nitrogen species in pain. *Free Radic. Biol. Med.* **51,** 951–966 (2011).
1290 92. Bautista, D. M., Jordt, S. E., Nikai, T., Tsuruda, P. R., Read, A. J., Poblete, J., Yamoah,
1291 E. N., Basbaum, A. I. & Julius, D. TRPA1 Mediates the Inflammatory Actions of
1292 Environmental Irritants and Proalgesic Agents. *Cell* **124,** 1269–1282 (2006).
1293 93. Liu, T. & Ji, R.-R. Oxidative stress induces itch via activation of transient receptor
1294 potential subtype ankyrin 1 in mice. *Neurosci Bull* **28,** 145–154 (2012).
1295 94. Caceres, A. I., Brackmann, M., Elia, M. D., Bessac, B. F., del Camino, D.,
1296 D'Amours, M., Witek, J. S., Fanger, C. M., Chong, J. A., Hayward, N. J., Homer, R.
1297 J., Cohn, L., Huang, X., Moran, M. M. & Jordt, S.-E. A sensory neuronal ion channel
1298 essential for airway inflammation and hyperreactivity in asthma. *Proc. Natl. Acad. Sci.*
1299 *U.S.A.* **106,** 9099–9104 (2009).
1300 95. Wang, J. Neutrophils in tissue injury and repair. *Cell Tissue Res.* **371,** 531–539 (2018).
1301 96. Hammond, T. R., Robinton, D. & Stevens, B. Microglia and the Brain: Complementary

Partners in Development and Disease. *Annu. Rev. Cell Dev. Biol.* **34,** 523–544 (2018).
97. Brunner, P. M., Guttman-Yassky, E. & Leung, D. Y. M. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. *J. Allergy Clin. Immunol.* **139,** S65–S76 (2017).
98. Li, C., Maillet, I., Mackowiak, C., Viala, C., Padova, F. Di, Li, M., Togbe, D., Quesniaux, V., Lai, Y. & Ryffel, B. Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells. *Cell Death Dis.* **8,** (2017).
99. Saunders, S. P., Moran, T., Floudas, A., Wurlod, F., Kaszlikowska, A., Salimi, M., Quinn, E. M., Oliphant, C. J., Núñez, G., McManus, R., Hams, E., Irvine, A. D., McKenzie, A. N. J., Ogg, G. S. & Fallon, P. G. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic March requiring adaptive immunity. *J. Allergy Clin. Immunol.* **137,** 482–491 (2016).
100. Andersson, S. The role of mast cells and mast cell mediators in the development of atopic dermatitis in a mouse model. 52 (2014).
101. Liu, B., Tai, Y., Liu, B., Caceres, A. I., Yin, C. & Jordt, S.-E. Transcriptome profiling reveals Th2 bias and identifies endogenous itch mediators in poison ivy contact dermatitis. *JCI Insight* (2019). doi:10.1172/jci.insight.124497
102. Malik, K., Ungar, B., Garcet, S., Dutt, R., Dickstein, D., Zheng, X., Xu, H., Estrada, Y. D., Suárez-Fariñas, M., Shemer, A., Krueger, J. G. & Guttman-Yassky, E. Dust mite induces multiple polar T cell axes in human skin. *Clin. Exp. Allergy* **47,** 1648–1660 (2017).
103. Qu, L., Fu, K., Shimada, S. G. & LaMotte, R. H. Cl^- channel is required for CXCL10-induced neuronal activation and itch response in a murine model of allergic contact dermatitis. *J. Neurophysiol.* **118,** 619–624 (2017).
104. Jing, P. B., Cao, D. L., Li, S. S., Zhu, M., Bai, X. Q., Wu, X. B. & Gao, Y. J. Chemokine Receptor CXCR3 in the Spinal Cord Contributes to Chronic Itch in Mice. *Neurosci. Bull.* **34,** 54–63 (2018).
105. Hamilton, J. D., Su??rez-Fari??as, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., Yancopoulos, G. D., Pirozzi, G. & Guttman-Yassky, E. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. *J. Allergy Clin. Immunol.* **134,** 1293–1300 (2014).
106. Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., Ardeleanu, M. & Investigators, S. 1 and S. 2. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N. Engl. J. Med.* **375,** 2335–2348 (2016).
107. Yellin, M., Paliienko, I., Balanescu, A., Ter-Vartanian, S., Tseluyko, V., Xu, L. A., Tao, X., Cardarelli, P. M., Leblanc, H., Nichol, G., Ancuta, C., Chirieac, R. & Luo, A. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum.* **64,** 1730–1739 (2012).
108. Scott, D., Wolfe, F. & Huizinga, T. Rheumatoid arthritis. *Lancet* **376,** 53–79 (2010).
109. Liu, B., Tai, Y., Achanta, S., Kaelberer, M. M., Caceres, A. I., Shao, X. & Fang, J. IL-33 / ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy. **1,** (2016).
110. Baral, P., Umans, B. D., Li, L., Wallrapp, A., Bist, M., Kirschbaum, T., Wei, Y., Zhou, Y., Kuchroo, V. K., Burkett, P. R., Yipp, B. G., Liberles, S. D. & Chiu, I. M. Nociceptor sensory neurons suppress neutrophil and γδ T cell responses in bacterial lung infections and lethal pneumonia. *Nat. Med.* **24,** 417–426 (2018).
111. Pinho-Ribeiro, F. A., Verri, W. A. & Chiu, I. M. Nociceptor Sensory Neuron–Immune

Interactions in Pain and Inflammation. *Trends Immunol.* **38,** 5–19 (2017).

112. Blake, K. J., Baral, P., Voisin, T., Lubkin, A., Pinho-Ribeiro, F. A., Adams, K. L., Roberson, D. P., Ma, Y. C., Otto, M., Woolf, C. J., Torres, V. J. & Chiu, I. M. Staphylococcus aureus produces pain through pore-forming toxins and neuronal TRPV1 that is silenced by QX-314. *Nat. Commun.* **9,** (2018).
113. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10,** R25 (2009).
114. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9,** 357–359 (2012).
115. Anders, S. & Huber, W. Differential expression of RNA-Seq data at the gene level–the DESeq package. *Heidelberg* (2012). at <http://watson.nci.nih.gov/bioc_mirror/packages/2.11/bioc/vignettes/DESeq/inst/doc/DESeq.pdf>
116. Anders, S., McCarthy, D. J., Chen, Y., Okoniewski, M., Smyth, G. K., Huber, W. & Robinson, M. D. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. *Nat Protoc* **8,** 1765–1786 (2013).
117. Hill, R. Z., Hoffman, B. U., Morita, T., Campos, S. M., Lumpkin, E. A., Brem, R. B. & Bautista, D. M. The signaling lipid sphingosine 1-phosphate regulates mechanical pain. *Elife* **7,** e33285 (2018).
118. Marshall, K. L., Clary, R. C., Baba, Y., Orlowsky, R. L., Gerling, G. J. & Lumpkin, E. A. Touch Receptors Undergo Rapid Remodeling in Healthy Skin. *Cell Rep.* **17,** 1719–1727 (2016).
119. Wilson, S. R., Gerhold, K. A., Bifolck-Fisher, A., Liu, Q., Patel, K. N., Dong, X. & Bautista, D. M. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. *Nat. Neurosci.* **14,** 595–602 (2011).
120. Morita, T., McClain, S. P. P., Batia, L. M. M., Pellegrino, M., Wilson, S. R. R., Kienzler, M. A. A., Lyman, K., Olsen, A. S. B. S. B., Wong, J. F. F., Stucky, C. L. L., Brem, R. B. B. & Bautista, D. M. M. HTR7 Mediates Serotonergic Acute and Chronic Itch. *Neuron* **87,** 124–138 (2015).
121. von Moltke, J., Trinidad, N. J., Moayeri, M., Kintzer, A. F., Wang, S. B., Van Rooijen, N., Brown, C. R., Krantz, B. A., Leppla, S. H., Gronert, K. & Vance, R. E. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. *Nat. Publ. Gr.* **490,** 107–111 (2012).
122. Sapieha, P., Stahl, A., Chen, J., Seaward, M. R., Willett, K. L., Krah, N. M., Dennison, R. J., Connor, K. M., Aderman, C. M., Liclican, E., Carughi, A., Perelman, D., Kanaoka, Y., Sangiovanni, J. P., Gronert, K. & Smith, L. E. H. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids. *Sci Transl Med* **3,** 69ra12-69ra12 (2011).


A
AD gene groups
Med. abs. log2 f.c.
AD disease
Axon guidance
Basos/Eos
Neutrophils
DCs
T cell
Th2
Keratin
Protease
B
Skin AD genes
D1
D2
D5
D8
log2 fold change
C
MC903 itch
Scratch time(s)
MC903
EtOH
ns
Day 3
Day 5
Day 8
D
Chemokine/cytokine expression
Neutrophil
Cxcl1
Cxcl2
Cxcl3
Cxcl5
Th2
Il33
Il4
Tslp
T cell
Cxcl9
Cxcl10
Cxcl11
log2 f.c. MC903 vs. EtOH
Day 1
Day 2
Day 5
Day 8
Immune cell recruitment
E
Neutrophils
Cell count
F
Basophils
G
CD4+ T cells
H
Day 2 innervation
BTIII
EtOH
MC903
I
BTIII
% area innervated
J
CGRP



Figure 1-Figure Supplement 1



Figure 1-Figure Supplement 2



Figure 1-Figure Supplement 3

A



Figure 1-Figure Supplement 4



Figure 1-Figure Supplement 5

A SLIGRL-treated human keratinocytes



Figure 1-Figure Supplement 6



Figure 1-Figure Supplement 7



Figure 1-Figure Supplement 8

A

Day 2 CGRP innervation



Figure 1-Figure Supplement 9

A



Figure 1-Figure Supplement 10


A
MC903 itch
MC903
EtOH
MC903 + aGr1
Scratch time (s)
Day 3
Day 5
Day 8
B
Neutrophils
Cell count
MC903
EtOH
MC903 + aGr1
C
Basophils
D
CD4+ T cells
E
CXCL1 acute itch
CXCL1
PBS
aGr1+CXCL1
aGR1+PBS
F
MC903 chronic itch
WT MC903
WT EtOH
TSLPR KO MC903
TSLPR KO EtOH
Day 8
Day 12
G
H
I
J
Day 12 neutrophils
K
MC903 Day 12 itch
MC903 + PBS

Figure 2



Figure 2-Figure Supplement 1



Figure 2-Figure Supplement 2

A



Figure 2-Figure Supplement 3



Figure 2-Figure Supplement 4



Figure 2-Figure Supplement 5


A
Genes in TG
Med. abs. log2 f.c.
2.0
1.5
1.0
0.5
0.0
(7)
(8)
(9)
(3)
**
**
**
*
Excitability
Immune
Neuroinfl.
IEGs
B
Genes in TG
Tmem173
Adamts8
Avpr1a
Serpina3n
Nppb
Il31ra
Serpina3g
Cysltr2
Fst
Lox
Car12
Steap1
Accsl
Vgf
Bdnf
Sectm1b
Fam150b
Serpina3i
Itk
Plin4
Rag1
F2rl1
Igkc
2310043M15Ri
Mt1
Cd19
Cyp2d22
Junb
Nxpe4
Sdc1
Fosl2
Cebpd
Etnppl
Timeless
Capn9
Tifa
Nt5e
Slc10a6
Tmem79
Nptx1
Osmr
Trpa1
Sbno2
Foxl2os
Cxcl9
Pmp2
AW112010
Mfap4
Gm5734
Mrgprb5
Chodl
Tgfbi
Mmp2
Col14a1
H2-Eb1
H2-Ab1
Dbp
Cd74
Gdf10
Cpz
Fgl2
Igfbp5
Kctd12
Sfrp4
H2-Aa
Themis2
Tgtp2
Smoc2
Col12a1
Shisa3
Gvin1
Gm4070
D1
D2
D5
D8
log2 fold change
4
2
0
-2
-4
Day 5 TG
C
Vehicle
CD45
Prph
MC903
CD45
Prph
D
# of CD45+ cells
120
80
40
0
ns
MC903
EtOH
CD45+:Prph+
4
3
2
1
0
ns
MC903
EtOH
Day 8 TG
E
Vehicle
CD45
Prph
MC903
CD45
Prph
F
# of CD45+ cells
120
80
40
0
**
MC903
EtOH
CD45+:Prph+
4
3
2
1
0
**
MC903
EtOH
G
Day 8 spinal cord
Norm. read counts
800
600
400
200
0
****
****
*
MC903
EtOH
Lcn2
Fos
Junb

Figure 3



Figure 3-Figure Supplement 1


A
Th2 genes
WT
WT aGr1
TSLPR KO
log2 fold change
Il33
Il4
Tslp
B
Chemokines
log2 fold change
Cxcl1
Cxcl2
Cxcl3
Cxcl5
Cxcl9
Cxcl10
Cxcl11
C
Activity-induced genes in TG
log2 fold change
Vgf
Fosl2
Junb
D
Spinal cord
log2 fold change
Lcn2
Fos
Junb
E
Day 2 innervation
aGr1
ns
% area innervated
MC903
EtOH
F
ELISA of CXCL10 in skin
Control
aGr1
TSLPR KO
ng/mL CXCL10
*
ns
*
MC903
EtOH
G
Itch behavior
MC903
CQ
VEH
AMG 487
Scratch time (s)
*
***
****
ns
Day 5
Day 8
Day 12
VEH
AMG 487

Figure 4



Figure 4-Figure Supplement 1

A


Protease activity
Barrier dysfunction
Neutrophil chemokines:
CXCL1,2,3,5
Neutrophil-dependent
CXCL10
Itch-evoked scratching
CXCR3+ sensory neuron
Early itch
Neutrophils
Increased scratching
TSLP
IL-4
Chronic itch
Basophils
TSLPR+/IL4Rα+
sensory neuron
CD4+ T cell

Figure 5